{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:32:22Z","timestamp":1790742742525,"version":"4.1.0"},"reference-count":252,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural Research Program, Center of Cancer Research, National Cancer Institute, National Institutes of Health","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}]},{"name":"National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The field of chimeric antigen receptor (CAR) T-cell therapy has grown from a fully experimental concept to now boasting a multitude of treatments including six FDA-approved products targeting various hematologic malignancies. Yet, along with their efficacy, these therapies come with side effects requiring timely and thoughtful interventions. In this review, we discuss the most common toxicities associated with CAR T-cells to date, highlighting risk factors, prognostication, implications for critical care management, patient experience optimization, and ongoing work in the field of toxicity mitigation. Understanding the current state of the field and standards of practice is critical in order to improve and manage potential toxicities of both current and novel CAR T-cell therapies as they are applied in the clinic.<\/jats:p>","DOI":"10.1007\/s10555-024-10227-1","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T21:50:56Z","timestamp":1734213056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Evolving strategies for addressing CAR T-cell toxicities"],"prefix":"10.1007","volume":"44","author":[{"given":"Alexander W.","family":"Rankin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynn B.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Silbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"issue":"16","key":"10227_CR1","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., & June, C. H. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509\u20131518. https:\/\/doi.org\/10.1056\/NEJMoa1215134","journal-title":"New England Journal of Medicine"},{"key":"10227_CR2","doi-asserted-by":"publisher","unstructured":"Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., . . . Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"10227_CR3","doi-asserted-by":"publisher","unstructured":"Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., Bories, P., Bay, J. O., Llorente, C. C., Choquet, S., Casasnovas, R. O., Mohty, M., Guidez, S., Joris, M., Loschi, M., . . . Morschhauser, F. (2022). A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine, 28(10), 2145\u20132154. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","DOI":"10.1038\/s41591-022-01969-y"},{"issue":"16_suppl","key":"10227_CR4","doi-asserted-by":"publisher","first-page":"7528","DOI":"10.1200\/JCO.2023.41.16_suppl.7528","volume":"41","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J., Amoloja, T., Burke, L. M., Morariu-Zamfir, R., Bhatt, V., Bibeau, K., Tang, X. Y., Moskop, A., Maziarz, R. T., & DiPersio, J. F. (2023). Rates of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T). Journal of Clinical Oncology, 41(16_suppl), 7528\u20137528. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.7528","journal-title":"Journal of Clinical Oncology"},{"key":"10227_CR5","doi-asserted-by":"publisher","unstructured":"Brammer, J. E., Braunstein, Z., Katapadi, A., Porter, K., Biersmith, M., Guha, A., Vasu, S., Yildiz, V. O., Smith, S. A., Buck, B., Haddad, D., Gumina, R., William, B. M., Penza, S., Saad, A., Denlinger, N., Vallakati, A., Baliga, R., Benza, R., . . . Addison, D. (2021). Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. Journal for Immunotherapy of Cancer, 9(8). https:\/\/doi.org\/10.1136\/jitc-2020-002303","DOI":"10.1136\/jitc-2020-002303"},{"key":"10227_CR6","doi-asserted-by":"publisher","unstructured":"Tang, K., & Nastoupil, L. J. (2021). Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: How similar are they to the prospective studies? J Immunother Precis Oncol, 4(3), 150\u2013159. https:\/\/doi.org\/10.36401\/jipo-21-2","DOI":"10.36401\/jipo-21-2"},{"issue":"10","key":"10227_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin, J. R., Kersten, M. J., Salles, G., Abramson, J. S., Schuster, S. J., Locke, F. L., & Andreadis, C. (2021). Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. American Journal of Hematology, 96(10), 1295\u20131312. https:\/\/doi.org\/10.1002\/ajh.26301","journal-title":"American Journal of Hematology"},{"key":"10227_CR8","doi-asserted-by":"publisher","unstructured":"Pasquini, M. C., Hu, Z. H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., Salzberg, D., Jaglowski, S., Sasine, J. P., Rosenthal, J., Ghosh, M., Landsburg, D., Margossian, S., Martin, P. L., Kamdar, M. K., . . . Grupp, S. (2020). Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 4(21), 5414\u20135424. https:\/\/doi.org\/10.1182\/bloodadvances.2020003092","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"10227_CR9","doi-asserted-by":"publisher","unstructured":"Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., Fry, T. J., Holter-Chakrabarty, J. L., Komanduri, K. V., Lee, D. W., Locke, F. L., Maude, S. L., McCarthy, P. L., Mead, E., Neelapu, S. S., . . . Grupp, S. A. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for Immunotherapy of Cancer, 8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001511","DOI":"10.1136\/jitc-2020-001511"},{"key":"10227_CR10","doi-asserted-by":"publisher","unstructured":"Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Barz Leahy, A., Callahan, C., Dolan, J. G., Fitzgerald, J. C., Gladney, W., Lacey, S. F., Liu, H., Maude, S. L., McGuire, R., Motley, L. S., Teachey, D. T., Wertheim, G. B., Wray, L., . . . Grupp, S. A. (2021). Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. Journal of Clinical Oncology, 39(8), 920\u2013930. https:\/\/doi.org\/10.1200\/jco.20.02477","DOI":"10.1200\/jco.20.02477"},{"issue":"1","key":"10227_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2020.09.028","volume":"27","author":"AS Kittai","year":"2021","unstructured":"Kittai, A. S., Huang, Y., Gordon, M., Denlinger, N., Mian, A., Fitzgerald, L., Bishop, J., Nagle, S., Stephens, D. M., Jaglowski, S., Hill, B., & Danilov, A. V. (2021). Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: A multicenter analysis. Transplantation and Cellular Therapy, 27(1), 46\u201352. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.028","journal-title":"Transplantation and Cellular Therapy"},{"issue":"20","key":"10227_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood.2022017604","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso, B. D., Gust, J., & Perna, F. (2023). How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood, 141(20), 2443\u20132451. https:\/\/doi.org\/10.1182\/blood.2022017604","journal-title":"Blood"},{"issue":"6","key":"10227_CR13","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1212\/cpj.0000000000001078","volume":"11","author":"Y Aghajan","year":"2021","unstructured":"Aghajan, Y., Yu, A., Jacobson, C. A., Kim, A. I., Kean, L., Robertson, M., & Vaitkevicius, H. (2021). Myelopathy because of CAR-T-related neurotoxicity treated with siltuximab. Neurology: Clinical Practice, 11(6), e944\u2013e946. https:\/\/doi.org\/10.1212\/cpj.0000000000001078","journal-title":"Neurology: Clinical Practice"},{"issue":"1","key":"10227_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30741","volume":"71","author":"H Shalabi","year":"2024","unstructured":"Shalabi, H., Harrison, C., Yates, B., Calvo, K. R., Lee, D. W., & Shah, N. N. (2024). Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome. Pediatric Blood & Cancer, 71(1), e30741. https:\/\/doi.org\/10.1002\/pbc.30741","journal-title":"Pediatric Blood & Cancer"},{"key":"10227_CR15","doi-asserted-by":"publisher","unstructured":"Cohen, A. D., Parekh, S., Santomasso, B. D., G\u00e1llego P\u00e9rez-Larraya, J., van de Donk, N., Arnulf, B., Mateos, M. V., Lendvai, N., Jackson, C. C., De Braganca, K. C., Schecter, J. M., Marquez, L., Lee, E., Cornax, I., Zudaire, E., Li, C., Olyslager, Y., Madduri, D., Varsos, H., . . . Jagannath, S. (2022). Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 12(2), 32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","DOI":"10.1038\/s41408-022-00629-1"},{"issue":"8","key":"10227_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood.2019004000","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill, J. A., & Seo, S. K. (2020). How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 136(8), 925\u2013935. https:\/\/doi.org\/10.1182\/blood.2019004000","journal-title":"Blood"},{"key":"10227_CR17","doi-asserted-by":"publisher","unstructured":"Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, G. M., Marsh, R. A., Neelapu, S. S., Nikiforow, S., Ombrello, A. K., Shah, N. N., Talleur, A. C., . . . Shah, N. N. (2023). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy, 29(7), 438.e431\u2013438.e416. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006","DOI":"10.1016\/j.jtct.2023.03.006"},{"issue":"19","key":"10227_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M. C., Fagioli, F., Ahlmann, M., Dapena Diaz, J. L., Henry, M., De Benedetti, F., Grom, A., Lapeyre, G., Jacqmin, P., Ballabio, M., & de Min, C. (2020). Emapalumab in children with primary hemophagocytic lymphohistiocytosis. New England Journal of Medicine, 382(19), 1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1911326","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10227_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjh.18454","volume":"199","author":"TJ Porter","year":"2022","unstructured":"Porter, T. J., Lazarevic, A., Ziggas, J. E., Fuchs, E., Kim, K., Byrnes, H., Luznik, L., Bola\u00f1os-Meade, J., Ali, S. A., Shah, N. N., Wagner-Johnston, N., & Jain, T. (2022). Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. British Journal of Haematology, 199(5), 720\u2013727. https:\/\/doi.org\/10.1111\/bjh.18454","journal-title":"British Journal of Haematology"},{"key":"10227_CR20","doi-asserted-by":"publisher","unstructured":"Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., Ciceri, F., Corradini, P., Delgado, J., Di Blasi, R., Greco, R., Houot, R., Iacoboni, G., J\u00e4ger, U., Kersten, M. J., . . . Yakoub-Agha, I. (2023). Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood, 142(10), 865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","DOI":"10.1182\/blood.2023020578"},{"key":"10227_CR21","doi-asserted-by":"publisher","unstructured":"McNerney, K. O., Si Lim, S. J., Ishikawa, K., Dreyzin, A., Vatsayan, A., Chen, J. J., Baggott, C., Prabhu, S., Pacenta, H. L., Philips, C., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Verneris, M., Myers, D., Karras, N. A., Brown, P., Bonifant, C. L., . . . Schultz, L. M. (2023). HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Advances, 7(12), 2758\u20132771. https:\/\/doi.org\/10.1182\/bloodadvances.2022008893","DOI":"10.1182\/bloodadvances.2022008893"},{"key":"10227_CR22","doi-asserted-by":"publisher","unstructured":"Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, E., Weng, W. K., Shiraz, P., Rezvani, A., Latchford, T., Mackall, C., Miklos, D., . . . Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 5(21), 4465\u20134475. https:\/\/doi.org\/10.1182\/bloodadvances.2021004716","DOI":"10.1182\/bloodadvances.2021004716"},{"key":"10227_CR23","doi-asserted-by":"publisher","unstructured":"Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., Gust, J., Lim, M., Majzner, R. G., Park, J. R., Partap, S., Ramakrishna, S., Richards, R., Schultz, L., Vitanza, N. A., . . . Monje, M. (2023). Tumor inflammation-associated neurotoxicity. Nature Medicine, 29(4), 803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","DOI":"10.1038\/s41591-023-02276-w"},{"key":"10227_CR24","doi-asserted-by":"publisher","unstructured":"Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, A. Y., Gillespie, S. M., Toland, A. M. S., Mahdi, J., Reschke, A., Nie, E. H., Chau, I. J., . . . Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934\u2013941. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","DOI":"10.1038\/s41586-022-04489-4"},{"issue":"4","key":"10227_CR25","doi-asserted-by":"publisher","first-page":"ofx70","DOI":"10.1093\/ofid\/ofx170","volume":"4","author":"AA Appa","year":"2017","unstructured":"Appa, A. A., Jain, R., Rakita, R. M., Hakimian, S., & Pottinger, P. S. (2017). Characterizing cefepime neurotoxicity: A systematic review. Open Forum Infectious Diseases, 4(4), ofx70. https:\/\/doi.org\/10.1093\/ofid\/ofx170","journal-title":"Open Forum Infectious Diseases"},{"key":"10227_CR26","doi-asserted-by":"publisher","unstructured":"Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., . . . Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","DOI":"10.1056\/NEJMoa1709866"},{"key":"10227_CR27","doi-asserted-by":"publisher","unstructured":"Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., Kato, K., Harigae, H., Kersten, M. J., Andreadis, C., Riedell, P. A., Ho, P. J., P\u00e9rez-Sim\u00f3n, J. A., Chen, A. I., Nastoupil, L. J., . . . Thieblemont, C. (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nature Medicine, 28(2), 325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","DOI":"10.1038\/s41591-021-01622-0"},{"key":"10227_CR28","doi-asserted-by":"publisher","unstructured":"Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I., Rabitsch, W., Kwong, Y. L., Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., . . . Westin, J. R. (2022). Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med, 386(7), 629\u2013639. https:\/\/doi.org\/10.1056\/NEJMoa2116596","DOI":"10.1056\/NEJMoa2116596"},{"key":"10227_CR29","doi-asserted-by":"publisher","unstructured":"Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., J\u00e4ger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., . . . Maziarz, R. T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","DOI":"10.1056\/NEJMoa1804980"},{"key":"10227_CR30","doi-asserted-by":"publisher","unstructured":"Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., . . . Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","DOI":"10.1056\/NEJMoa1707447"},{"key":"10227_CR31","doi-asserted-by":"publisher","unstructured":"Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Yakoub-Agha, I., Oluwole, O. O., Fung, H. C. H., Rosenblatt, J., Rossi, J. M., Goyal, L., Plaks, V., . . . Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. The Lancet Haematology, 23(1), 91\u2013103. https:\/\/doi.org\/10.1016\/s1470-2045(21)00591-x","DOI":"10.1016\/s1470-2045(21)00591-x"},{"key":"10227_CR32","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M. A., Kersten, M. J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Mu\u00f1oz, J., Farooq, U., van Meerten, T., Reagan, P. M., Sureda, A., Flinn, I. W., Vandenberghe, P., Song, K. W., Dickinson, M., . . . Westin, J. R. (2022). Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine, 386(7), 640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","DOI":"10.1056\/NEJMoa2116133"},{"key":"10227_CR33","doi-asserted-by":"publisher","unstructured":"Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., . . . Reagan, P. M. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 382(14), 1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","DOI":"10.1056\/NEJMoa1914347"},{"key":"10227_CR34","doi-asserted-by":"publisher","unstructured":"Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., O'Dwyer, K. M., Arellano, M. L., Lin, Y., Baer, M. R., Schiller, G. J., Park, J. H., Subklewe, M., Abedi, M., Minnema, M. C., . . . Houot, R. (2021). KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, 398(10299), 491\u2013502. https:\/\/doi.org\/10.1016\/s0140-6736(21)01222-8","DOI":"10.1016\/s0140-6736(21)01222-8"},{"key":"10227_CR35","doi-asserted-by":"publisher","unstructured":"Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., . . . Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396(10254), 839\u2013852. https:\/\/doi.org\/10.1016\/s0140-6736(20)31366-0","DOI":"10.1016\/s0140-6736(20)31366-0"},{"key":"10227_CR36","doi-asserted-by":"publisher","unstructured":"Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., Izutsu, K., Morschhauser, F., Lunning, M., Maloney, D. G., Crotta, A., Montheard, S., Previtali, A., Stepan, L., Ogasawara, K., . . . Abramson, J. S. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), 2294\u20132308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6","DOI":"10.1016\/s0140-6736(22)00662-6"},{"key":"10227_CR37","doi-asserted-by":"publisher","unstructured":"Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N., Dubowy, R., D'Andrea, A., Wang, L., . . . Gordon, L. I. (2022). Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncology, 23(8), 1066\u20131077. https:\/\/doi.org\/10.1016\/s1470-2045(22)00339-4","DOI":"10.1016\/s1470-2045(22)00339-4"},{"key":"10227_CR38","doi-asserted-by":"publisher","unstructured":"Munshi, N. C., Anderson, L. D., Jr., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., . . . San-Miguel, J. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","DOI":"10.1056\/NEJMoa2024850"},{"key":"10227_CR39","doi-asserted-by":"publisher","unstructured":"Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., . . . Giralt, S. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388(11), 1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2213614","DOI":"10.1056\/NEJMoa2213614"},{"key":"10227_CR40","doi-asserted-by":"publisher","unstructured":"Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., . . . Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study. Lancet, 398(10297), 314\u2013324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8","DOI":"10.1016\/s0140-6736(21)00933-8"},{"key":"10227_CR41","doi-asserted-by":"publisher","unstructured":"San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fern\u00e1ndez de Larrea, C., Mart\u00ednez-L\u00f3pez, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N., Dytfeld, D., Sidana, S., . . . Einsele, H. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389(4), 335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa2303379","DOI":"10.1056\/NEJMoa2303379"},{"issue":"8","key":"10227_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018). FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist, 23(8), 943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028","journal-title":"The Oncologist"},{"key":"10227_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., Boughan, K., Hillian, A., Reese-Koc, J., Maschan, M., Dropulic, B., Sekaly, R. P., & de Lima, M. (2021). Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Frontiers in Immunology, 12, 745320. https:\/\/doi.org\/10.3389\/fimmu.2021.745320","journal-title":"Frontiers in Immunology"},{"key":"10227_CR44","doi-asserted-by":"publisher","unstructured":"Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., . . . Brentjens, R. (2014). Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Transplantation and Cellular Therapy, 6(224), 224ra225. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"4","key":"10227_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018). Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit \u2018ALL.\u2019 Nature Reviews. Clinical Oncology, 15(4), 218. https:\/\/doi.org\/10.1038\/nrclinonc.2018.19","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"10227_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., Song, Y., Zhao, Y., & Tong, C. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 10(2), 15. https:\/\/doi.org\/10.1038\/s41408-020-0280-y","journal-title":"Blood Cancer Journal"},{"issue":"24","key":"10227_CR47","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., Finney, O. C., Brakke, H., Li, D. H., Park, J. R., & Jensen, M. C. (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood, 134(24), 2149\u20132158. https:\/\/doi.org\/10.1182\/blood.2019001463","journal-title":"Blood"},{"key":"10227_CR48","doi-asserted-by":"publisher","unstructured":"Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O'Dwyer, K. M., Holmes, H., Arellano, M. L., Ghobadi, A., Pagel, J. M., Lin, Y., Cassaday, R. D., Park, J. H., Abedi, M., Castro, J. E., DeAngelo, D. J., Malone, A. K., Mawad, R., . . . Wierda, W. G. (2021). KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 138(1), 11\u201322. https:\/\/doi.org\/10.1182\/blood.2020009098","DOI":"10.1182\/blood.2020009098"},{"issue":"20","key":"10227_CR49","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain, M. D., Smith, M., & Shah, N. N. (2023). How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood, 141(20), 2430\u20132442. https:\/\/doi.org\/10.1182\/blood.2022017414","journal-title":"Blood"},{"issue":"5","key":"10227_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/jco.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., Grupp, S. A., Shah, N. N., Gilmore, J., Lacey, S. F., Melenhorst, J. J., Levine, B. L., June, C. H., & Porter, D. L. (2020). Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. Journal of Clinical Oncology, 38(5), 415\u2013422. https:\/\/doi.org\/10.1200\/jco.19.01892","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10227_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A. M., Loghin, M. E., de Groot, J. F., Adkins, S., Davis, S. E., Rezvani, K., Hwu, P., & Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy - Assessment and management of toxicities. Nature Reviews. Clinical Oncology, 15(1), 47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"10","key":"10227_CR52","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1634\/theoncologist.2019-0646","volume":"25","author":"I Papadouli","year":"2020","unstructured":"Papadouli, I., Mueller-Berghaus, J., Beuneu, C., Ali, S., Hofner, B., Petavy, F., Tzogani, K., Miermont, A., Norga, K., Kholmanskikh, O., Leest, T., Schuessler-Lenz, M., Salmonson, T., Gisselbrecht, C., Garcia, J. L., & Pignatti, F. (2020). EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-Cell lymphoma. The Oncologist, 25(10), 894\u2013902. https:\/\/doi.org\/10.1634\/theoncologist.2019-0646","journal-title":"The Oncologist"},{"issue":"1","key":"10227_CR53","doi-asserted-by":"publisher","first-page":"77.e71","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson, C. A., Munoz, J., Sun, F., Kanters, S., Limbrick-Oldfield, E. H., Spooner, C., Mignone, K., Ayuk, F., Sanderson, R., Whitmore, J., Wang, Y., Xu, H., & Dickinson, M. (2024). Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis. Transplantation and Cellular Therapy, 30(1), 77.e71-77.e15. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.017","journal-title":"Transplantation and Cellular Therapy"},{"key":"10227_CR54","doi-asserted-by":"publisher","unstructured":"Santomasso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Funchain, P., Jaiyesimi, I., Mammen, J. S., Naidoo, J., Naing, A., Phillips, T., . . . Ghosh, M. (2021). Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. Journal of Clinical Oncology, 39(35), 3978\u20133992. https:\/\/doi.org\/10.1200\/jco.21.01992","DOI":"10.1200\/jco.21.01992"},{"issue":"5","key":"10227_CR55","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","volume":"106","author":"R Nair","year":"2021","unstructured":"Nair, R., Drillet, G., Lhomme, F., Le Bras, A., Michel, L., Rossi, J., Sherman, M., Xue, A., Kerber, A., Jittapiromsak, N., Chi, L., Tummala, S., Neelapu, S. S., & Houot, R. (2021). Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica, 106(5), 1504\u20131506. https:\/\/doi.org\/10.3324\/haematol.2020.259952","journal-title":"Haematologica"},{"key":"10227_CR56","doi-asserted-by":"publisher","unstructured":"Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., Scholler, J., Montine, T. J., Bhoj, V. G., Reddy, R., Mohan, S., Maillard, I., Kriegstein, A. R., June, C. H., Chang, H. Y., . . . Satpathy, A. T. (2020). Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell, 183(1), 126\u2013142.e117. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022","DOI":"10.1016\/j.cell.2020.08.022"},{"issue":"1","key":"10227_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jha2.286","volume":"3","author":"S Sheikh","year":"2022","unstructured":"Sheikh, S., Mokhtari, S., Silverman, J. A., Reid, K., Faramand, R., Davila, M. L., Franke, N., Locke, F. L., Jain, M. D., Wong, D., & Kuruvilla, J. G. (2022). Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 3(1), 223\u2013227. https:\/\/doi.org\/10.1002\/jha2.286","journal-title":"EJHaem"},{"key":"10227_CR58","doi-asserted-by":"publisher","unstructured":"Kathari, Y. K., Ahmad, H., Kallen, M. E., Koka, R., Omili, D., Iraguha, T., Clement, J., Pham, L., Khalid, M., Fan, X., Gebru, E., Lesho, P., Park, E., Dishanthan, N., Baker, J. M., Dietze, K. A., Hankey, K. G., Badros, A., Yared, J. A., . . . Atanackovic, D. (2024). Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica, 109(2), 682\u2013688. https:\/\/doi.org\/10.3324\/haematol.2023.283296","DOI":"10.3324\/haematol.2023.283296"},{"issue":"6","key":"10227_CR59","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.21873\/invivo.12640","volume":"35","author":"M Kuboki","year":"2021","unstructured":"Kuboki, M., Umezawa, Y., Motomura, Y., Okada, K., Nogami, A., Nagao, T., Miura, O., & Yamamoto, M. (2021). Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo, 35(6), 3407\u20133411. https:\/\/doi.org\/10.21873\/invivo.12640","journal-title":"In Vivo"},{"issue":"3","key":"10227_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41409-020-01029-4","volume":"56","author":"T Badar","year":"2021","unstructured":"Badar, T., Johnson, B. D., & Hamadani, M. (2021). Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 56(3), 683\u2013685. https:\/\/doi.org\/10.1038\/s41409-020-01029-4","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"10227_CR61","doi-asserted-by":"publisher","first-page":"305.e301","DOI":"10.1016\/j.jtct.2022.03.023","volume":"28","author":"AI Hoogland","year":"2022","unstructured":"Hoogland, A. I., Barata, A., Logue, J., Kommalapati, A., Hyland, K. A., Nelson, A. M., Eisel, S. L., Small, B. J., James, B. W., Christy, S. M., Bulls, H. W., Booth-Jones, M., Jayani, R. V., Jain, M. D., Mokhtari, S., Chavez, J. C., Lazaryan, A., Shah, B. D., Locke, F. L., & Jim, H. S. L. (2022). Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 28(6), 305.e301-305.e309. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.023","journal-title":"Transplantation and Cellular Therapy"},{"key":"10227_CR62","doi-asserted-by":"publisher","unstructured":"Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., Wang, X., Sikder, D., Senechal, B., Bermudez, V. P., Purdon, T. J., Hosszu, K., McAvoy, D. P., Farzana, T., Mead, E., . . . Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387(13), 1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","DOI":"10.1056\/NEJMoa2209900"},{"issue":"10","key":"10227_CR63","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J. A., & Boeckh, M. J. (2009). Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biology of Blood and Marrow Transplantation, 15(10), 1143\u20131238. https:\/\/doi.org\/10.1016\/j.bbmt.2009.06.019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"3","key":"10227_CR64","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/1521-4141(200103)31:3<939::aid-immu939>3.0.co;2-i","volume":"31","author":"M Pihlgren","year":"2001","unstructured":"Pihlgren, M., Schallert, N., Tougne, C., Bozzotti, P., Kovarik, J., Fulurija, A., Kosco-Vilbois, M., Lambert, P. H., & Siegrist, C. A. (2001). Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. European Journal of Immunology, 31(3), 939\u2013946. https:\/\/doi.org\/10.1002\/1521-4141(200103)31:3%3c939::aid-immu939%3e3.0.co;2-i","journal-title":"European Journal of Immunology"},{"key":"10227_CR65","doi-asserted-by":"publisher","unstructured":"Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P., Flinn, I. W., Farooq, U., Goy, A., McSweeney, P. A., Munoz, J., Siddiqi, T., . . . Neelapu, S. S. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial. Lancet Oncology, 20(1), 31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7","DOI":"10.1016\/s1470-2045(18)30864-7"},{"issue":"3","key":"10227_CR66","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/cid\/ciz1127","volume":"71","author":"G Haidar","year":"2020","unstructured":"Haidar, G., Dorritie, K., Farah, R., Bogdanovich, T., Nguyen, M. H., & Samanta, P. (2020). Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: A case series, review of the literature, and implications for prophylaxis. Clinical Infectious Diseases, 71(3), 672\u2013676. https:\/\/doi.org\/10.1093\/cid\/ciz1127","journal-title":"Clinical Infectious Diseases"},{"issue":"17","key":"10227_CR67","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam, H., Horne, A., Aric\u00f2, M., Egeler, R. M., Filipovich, A. H., Gadner, H., Imashuku, S., Ladisch, S., Webb, D., Janka, G., & Henter, J. I. (2011). Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118(17), 4577\u20134584. https:\/\/doi.org\/10.1182\/blood-2011-06-356261","journal-title":"Blood"},{"issue":"21","key":"10227_CR68","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.3390\/cancers15215149","volume":"15","author":"T Fugere","year":"2023","unstructured":"Fugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M., & Gentille Sanchez, C. G. (2023). Immune effector cell-associated HLH-like syndrome: A review of the literature of an increasingly recognized entity. Cancers (Basel), 15(21), 5149. https:\/\/doi.org\/10.3390\/cancers15215149","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10227_CR69","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain, T., Olson, T. S., & Locke, F. L. (2023). How I treat cytopenias after CAR T-cell therapy. Blood, 141(20), 2460\u20132469. https:\/\/doi.org\/10.1182\/blood.2022017415","journal-title":"Blood"},{"issue":"10","key":"10227_CR70","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","volume":"12","author":"KC Miller","year":"2022","unstructured":"Miller, K. C., Johnson, P. C., Abramson, J. S., Soumerai, J. D., Yee, A. J., Branagan, A. R., O\u2019Donnell, E. K., Saucier, A., Jacobson, C. A., Frigault, M. J., & Raje, N. S. (2022). Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer Journal, 12(10), 146. https:\/\/doi.org\/10.1038\/s41408-022-00741-2","journal-title":"Blood Cancer Journal"},{"key":"10227_CR71","doi-asserted-by":"publisher","unstructured":"Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., Schick, K. J., Walters, D. K., Ahmed, O., Chappell, D., Sahmoud, T., Durrant, C., Nevala, W. K., Patnaik, M. M., Pease, L. R., . . . Kenderian, S. S. (2019). GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 133(7), 697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722","DOI":"10.1182\/blood-2018-10-881722"},{"key":"10227_CR72","doi-asserted-by":"publisher","unstructured":"Peffault de Latour, R., Kulasekararaj, A., Iacobelli, S., Terwel, S. R., Cook, R., Griffin, M., Halkes, C. J. M., Recher, C., Barraco, F., Forcade, E., Vallejo, J. C., Drexler, B., Mear, J. B., Smith, A. E., Angelucci, E., Raymakers, R. A. P., de Groot, M. R., Daguindau, E., Nur, E., . . . Risitano, A. M. (2022). Eltrombopag added to immunosuppression in severe aplastic anemia. New England Journal of Medicine, 386(1), 11\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2109965","DOI":"10.1056\/NEJMoa2109965"},{"issue":"4","key":"10227_CR73","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann, N., Wulf, G. G., Duell, J., Glass, B., van Heteren, P., von Tresckow, B., Fischer, M., Penack, O., Ayuk, F., Einsele, H., Holtick, U., Thomson, J., Dreger, P., & Kr\u00f6ger, N. (2023). Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: A GLA\/DRST study. Blood Advances, 7(4), 555\u2013559. https:\/\/doi.org\/10.1182\/bloodadvances.2022008042","journal-title":"Blood Advances"},{"key":"10227_CR74","doi-asserted-by":"publisher","unstructured":"Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., Diamonte, C., Scordo, M., Sauter, C. S., Mead, E., Santomasso, B. D., Palomba, M. L., Batlevi, C. W., Maloy, M. A., Giralt, S., . . . Mailankody, S. (2020). Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 4(15), 3776\u20133787. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"10227_CR75","doi-asserted-by":"publisher","unstructured":"Lichtenstein, D. A., Schischlik, F., Shao, L., Steinberg, S. M., Yates, B., Wang, H. W., Wang, Y., Inglefield, J., Dulau-Florea, A., Ceppi, F., Hermida, L. C., Stringaris, K., Dunham, K., Homan, P., Jailwala, P., Mirazee, J., Robinson, W., Chisholm, K. M., Yuan, C., . . . Shah, N. N. (2021). Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 138(24), 2469\u20132484. https:\/\/doi.org\/10.1182\/blood.2021011898","DOI":"10.1182\/blood.2021011898"},{"key":"10227_CR76","doi-asserted-by":"crossref","unstructured":"Ma, L., Dou, Y., Liu, R., Xu, T., Yang, F., Xue, F., Zheng, P., Feng, S., Guo, Y., Shi, H., Deng, B., Ke, X., & Hu, K. (2022). P1206: Gastrointestinal bleeding significantly reduced the efficacy and survival of Cd19 Car-T cell therapy in patients with gastrointestinal tract involvement of refractory\/relapsed B-cell lymphoma. Hemasphere., 6(Suppl), 1092-1093. 1010.1097\/1001.HS1099.0000847688.0000801787.0000847613. eCollection 0000842022 Jun","DOI":"10.1097\/01.HS9.0000847688.01787.13"},{"key":"10227_CR77","doi-asserted-by":"publisher","unstructured":"Jess, J., Yates, B., Dulau-Florea, A., Parker, K., Inglefield, J., Lichtenstein, D., Schischlik, F., Ongkeko, M., Wang, Y., Shahani, S., Cullinane, A., Smith, H., Kane, E., Little, L., Chen, D., Fry, T. J., Shalabi, H., Wang, H. W., Satpathy, A., . . . Shah, N. N. (2023). CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. Journal for Immunotherapy of Cancer, 11(6). https:\/\/doi.org\/10.1136\/jitc-2022-005898","DOI":"10.1136\/jitc-2022-005898"},{"issue":"2","key":"10227_CR78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","volume":"5","author":"J Buechner","year":"2021","unstructured":"Buechner, J., Grupp, S. A., Hiramatsu, H., Teachey, D. T., Rives, S., Laetsch, T. W., Yanik, G. A., Wood, P., Awasthi, R., Yi, L., Chassot-Agostinho, A., Eldjerou, L. K., & De Moerloose, B. (2021). Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 5(2), 593\u2013601. https:\/\/doi.org\/10.1182\/bloodadvances.2020002757","journal-title":"Blood Advances"},{"issue":"7","key":"10227_CR79","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J., Mei, H., & Hu, Y. (2019). Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Annals of Hematology, 98(7), 1721\u20131732. https:\/\/doi.org\/10.1007\/s00277-019-03685-z","journal-title":"Annals of Hematology"},{"issue":"5","key":"10227_CR80","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","volume":"26","author":"Y Wang","year":"2020","unstructured":"Wang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., Yan, Z., Jing, G., Pan, B., Sang, W., Li, D., Wang, X., Fu, C., Zhu, F., Zheng, J., Li, Z., & Xu, K. (2020). Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biology of Blood and Marrow Transplantation, 26(5), 865\u2013875. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.027","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10227_CR81","doi-asserted-by":"publisher","unstructured":"Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadlowsky, J. K., Christensen, S., Oner, B. S., Plesa, G., Brennan, A., . . . O'Rourke, D. M. (2024). Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results. Nature Medicine, 30(5), 1320\u20131329. https:\/\/doi.org\/10.1038\/s41591-024-02893-z","DOI":"10.1038\/s41591-024-02893-z"},{"issue":"15","key":"10227_CR82","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","volume":"123","author":"S Gill","year":"2014","unstructured":"Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., June, C. H., & Kalos, M. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 123(15), 2343\u20132354. https:\/\/doi.org\/10.1182\/blood-2013-09-529537","journal-title":"Blood"},{"issue":"8","key":"10227_CR83","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","volume":"29","author":"SS Kenderian","year":"2015","unstructured":"Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V., Morrissette, J. J., Scholler, J., Song, D., Porter, D. L., Carroll, M., June, C. H., & Gill, S. (2015). CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 29(8), 1637\u20131647. https:\/\/doi.org\/10.1038\/leu.2015.52","journal-title":"Leukemia"},{"issue":"1","key":"10227_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.Cir-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018). High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunology Research, 6(1), 36\u201346. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0211","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"10227_CR85","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 18(4), 843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Molecular Therapy"},{"issue":"11","key":"10227_CR86","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., Chester, K. A., Westwood, N. B., Halford, S. E. R., Nabarro, S., Wan, S., Austin, E., & Hawkins, R. E. (2017). The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy, 66(11), 1425\u20131436. https:\/\/doi.org\/10.1007\/s00262-017-2034-7","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"8","key":"10227_CR87","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","volume":"29","author":"R Hassan","year":"2023","unstructured":"Hassan, R., Butler, M., O\u2019Cearbhaill, R. E., Oh, D. Y., Johnson, M., Zikaras, K., Smalley, M., Ross, M., Tanyi, J. L., Ghafoor, A., Shah, N. N., Saboury, B., Cao, L., Quint\u00e1s-Cardama, A., & Hong, D. (2023). Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: Phase 1\/2 trial interim results. Nature Medicine, 29(8), 2099\u20132109. https:\/\/doi.org\/10.1038\/s41591-023-02452-y","journal-title":"Nature Medicine"},{"key":"10227_CR88","doi-asserted-by":"publisher","unstructured":"Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., Binder-Scholl, G. K., Smethurst, D. P., Gerry, A. B., Pumphrey, N. J., Bennett, A. D., Brewer, J. E., Dukes, J., Harper, J., Tayton-Martin, H. K., . . . June, C. H. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122(6), 863\u2013871. https:\/\/doi.org\/10.1182\/blood-2013-03-490565","DOI":"10.1182\/blood-2013-03-490565"},{"issue":"10","key":"10227_CR89","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jtct.2023.07.016","volume":"29","author":"RM Myers","year":"2023","unstructured":"Myers, R. M., Jacoby, E., Pulsipher, M. A., Pasquini, M. C., Grupp, S. A., Shah, N. N., Laetsch, T. W., Curran, K. J., & Schultz, L. M. (2023). INSPIRED Symposium part 1: Clinical variables associated with improved outcomes for children and young adults treated with chimeric antigen receptor T cells for B cell acute lymphoblastic leukemia. Transplant Cell Therapy, 29(10), 598\u2013607. https:\/\/doi.org\/10.1016\/j.jtct.2023.07.016","journal-title":"Transplant Cell Therapy"},{"issue":"6","key":"10227_CR90","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews. Clinical Oncology, 20(6), 359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10227_CR91","doi-asserted-by":"publisher","unstructured":"Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., . . . Grupp, S. A. (2016). Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6(6), 664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0040","DOI":"10.1158\/2159-8290.Cd-16-0040"},{"issue":"21","key":"10227_CR92","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A., Hanafi, L. A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., L\u00f3pez, J. A., Chen, J., Chung, D., Harju-Baker, S., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2017). Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 130(21), 2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"12","key":"10227_CR93","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust, J., Taraseviciute, A., & Turtle, C. J. (2018). Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs, 32(12), 1091\u20131101. https:\/\/doi.org\/10.1007\/s40263-018-0582-9","journal-title":"CNS Drugs"},{"key":"10227_CR94","doi-asserted-by":"publisher","unstructured":"Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., . . . Laetsch, T. W. (2022). Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium report. Journal of Clinical Oncology, 40(9), 945\u2013955. https:\/\/doi.org\/10.1200\/jco.20.03585","DOI":"10.1200\/jco.20.03585"},{"key":"10227_CR95","doi-asserted-by":"publisher","unstructured":"Myers, R. M., Taraseviciute, A., Steinberg, S. M., Lamble, A. J., Sheppard, J., Yates, B., Kovach, A. E., Wood, B., Borowitz, M. J., Stetler-Stevenson, M., Yuan, C. M., Pillai, V., Foley, T., Chung, P., Chen, L., Lee, D. W., Annesley, C., DiNofia, A., Grupp, S. A., . . . Shah, N. N. (2022). Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal of Clinical Oncology, 40(9), 932\u2013944. https:\/\/doi.org\/10.1200\/jco.21.01405","DOI":"10.1200\/jco.21.01405"},{"key":"10227_CR96","doi-asserted-by":"publisher","unstructured":"Yan, Z., Zhang, H., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., Wang, Y., Gao, L., Shi, M., Sang, W., Zhu, F., Li, D., Sun, H., Wu, Q., Qi, Y., Li, H., . . . Xu, K. (2021). Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunology, 12, 611366. https:\/\/doi.org\/10.3389\/fimmu.2021.611366","DOI":"10.3389\/fimmu.2021.611366"},{"issue":"5","key":"10227_CR97","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H., Rivi\u00e8re, I., Gonen, M., Wang, X., S\u00e9n\u00e9chal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine, 378(5), 449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10227_CR98","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1182\/bloodadvances.2023009789","volume":"7","author":"SK Silbert","year":"2023","unstructured":"Silbert, S. K., Madan, S., Holland, E. M., Steinberg, S. M., Little, L., Foley, T., Epstein, M., Sarkisian, A., Lee, D. W., Nikitina, E., Kakumanu, S., Ruppin, E., Shalabi, H., Yates, B., & Shah, N. N. (2023). A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Advances, 7(18), 5566\u20135578. https:\/\/doi.org\/10.1182\/bloodadvances.2023009789","journal-title":"Blood Advances"},{"key":"10227_CR99","doi-asserted-by":"publisher","unstructured":"Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., Cross, J. R., Liu, H., Vachha, B., Chen, X., DeAngelis, L. M., Li, D., Bernal, Y., Gonen, M., Wendel, H. G., . . . Brentjens, R. J. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8(8), 958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1319","DOI":"10.1158\/2159-8290.Cd-17-1319"},{"key":"10227_CR100","doi-asserted-by":"publisher","unstructured":"Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., . . . Schultz, L. M. (2022). Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: A Pediatric Real World CAR Consortium report. Blood Advances, 6(2), 600\u2013610. https:\/\/doi.org\/10.1182\/bloodadvances.2021005564","DOI":"10.1182\/bloodadvances.2021005564"},{"issue":"7","key":"10227_CR101","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","volume":"6","author":"EM Holland","year":"2022","unstructured":"Holland, E. M., Yates, B., Ling, A., Yuan, C. M., Wang, H. W., Stetler-Stevenson, M., LaLoggia, M., Molina, J. C., Lichtenstein, D. A., Lee, D. W., Ligon, J. A., Shalabi, H., Ahlman, M. A., & Shah, N. N. (2022). Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Advances, 6(7), 2167\u20132182. https:\/\/doi.org\/10.1182\/bloodadvances.2021006035","journal-title":"Blood Advances"},{"key":"10227_CR102","doi-asserted-by":"publisher","unstructured":"Hay, K. A., Gauthier, J., Hirayama, A. V., Voutsinas, J. M., Wu, Q., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Schoch, G., Chapuis, A. G., Till, B. G., Kiem, H. P., Ramos, J. D., Shadman, M., . . . Turtle, C. J. (2019). Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 133(15), 1652\u20131663. https:\/\/doi.org\/10.1182\/blood-2018-11-883710","DOI":"10.1182\/blood-2018-11-883710"},{"issue":"10","key":"10227_CR103","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/s2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy, A. B., Newman, H., Li, Y., Liu, H., Myers, R., DiNofia, A., Dolan, J. G., Callahan, C., Baniewicz, D., Devine, K., Wray, L., Aplenc, R., June, C. H., Grupp, S. A., Rheingold, S. R., & Maude, S. L. (2021). CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: A post-hoc analysis of pooled data from five clinical trials. The Lancet Haematology, 8(10), e711\u2013e722. https:\/\/doi.org\/10.1016\/s2352-3026(21)00238-6","journal-title":"The Lancet Haematology"},{"key":"10227_CR104","doi-asserted-by":"publisher","unstructured":"Jacoby, E., Ghorashian, S., Vormoor, B., De Moerloose, B., Bodmer, N., Molostova, O., Yanir, A. D., Buechner, J., Elhasid, R., Bielorai, B., Rogosic, S., Dourthe, M. E., Maschan, M., Rossig, C., Toren, A., von Stackelberg, A., Locatelli, F., Bader, P., Zimmermann, M., . . . Baruchel, A. (2022). CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: A retrospective international study. Leukemia, 36(6), 1525\u20131532. https:\/\/doi.org\/10.1038\/s41375-022-01546-9","DOI":"10.1038\/s41375-022-01546-9"},{"key":"10227_CR105","doi-asserted-by":"publisher","unstructured":"Qi, Y., Zhao, M., Hu, Y., Wang, Y., Li, P., Cao, J., Shi, M., Tan, J., Zhang, M., Xiao, X., Xia, J., Ma, S., Qiao, J., Yan, Z., Li, H., Pan, B., Sang, W., Li, D., Li, Z., . . . Xu, K. (2022). Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 139(23), 3376\u20133386. https:\/\/doi.org\/10.1182\/blood.2021013733","DOI":"10.1182\/blood.2021013733"},{"key":"10227_CR106","doi-asserted-by":"publisher","unstructured":"Pennisi, M., Sanchez-Escamilla, M., Flynn, J. R., Shouval, R., Alarcon Tomas, A., Silverberg, M. L., Batlevi, C., Brentjens, R. J., Dahi, P. B., Devlin, S. M., Diamonte, C., Giralt, S., Halton, E. F., Jain, T., Maloy, M., Mead, E., Palomba, M. L., Ruiz, J., Santomasso, B., . . . Perales, M. A. (2021). Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 5(17), 3397\u20133406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885","DOI":"10.1182\/bloodadvances.2020003885"},{"key":"10227_CR107","doi-asserted-by":"publisher","unstructured":"Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Fr\u00f6lich, L., Ackermann, J., B\u00fccklein, V., Blumenberg, V., Schmidt, C., Jallades, L., Fehse, B., Faul, C., Karschnia, P., Weigert, O., Dreyling, M., Locke, F. L., . . . Subklewe, M. (2021). CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood, 138(24), 2499\u20132513. https:\/\/doi.org\/10.1182\/blood.2020010543","DOI":"10.1182\/blood.2020010543"},{"issue":"11","key":"10227_CR108","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K., Wang, Y., Albanyan, O., Munoz, J., Sesques, P., Iacoboni, G., Lopez-Corral, L., Ries, I., B\u00fccklein, V. L., Mohty, R., Dreyling, M., Baluch, A., Shah, B., Locke, F. L., Hess, G., Barba, P., Bachy, E., Lin, Y., Subklewe, M., & Jain, M. D. (2023). The CAR-`HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology, 98(11), 1699\u20131710. https:\/\/doi.org\/10.1002\/ajh.27056","journal-title":"American Journal of Hematology"},{"key":"10227_CR109","doi-asserted-by":"publisher","unstructured":"Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., Hoffman, L., Little, L., Ponduri, A., Qin, H., Qureshi, H., Dulau-Florea, A., Salem, D., Wang, H. W., Yuan, C., . . . Fry, T. J. (2020). CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: Updated results from a phase I anti-CD22 CAR T-cell trial. Journal of Clinical Oncology, 38(17), 1938\u20131950. https:\/\/doi.org\/10.1200\/jco.19.03279","DOI":"10.1200\/jco.19.03279"},{"issue":"1","key":"10227_CR110","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","volume":"21","author":"R Smith","year":"2023","unstructured":"Smith, R., & Shen, R. (2023). Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. Journal of Translational Medicine, 21(1), 515. https:\/\/doi.org\/10.1186\/s12967-023-04372-4","journal-title":"Journal of Translational Medicine"},{"issue":"5","key":"10227_CR111","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","volume":"30","author":"PC Johnson","year":"2024","unstructured":"Johnson, P. C., Neckermann, I., Sadrzadeh, H., Newcomb, R., El-Jawahri, A. R., & Frigault, M. J. (2024). Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 30(5), 490\u2013499. https:\/\/doi.org\/10.1016\/j.jtct.2024.02.019","journal-title":"Transplantation and Cellular Therapy"},{"key":"10227_CR112","doi-asserted-by":"publisher","unstructured":"Dreger, P., Holtick, U., Subklewe, M., von Tresckow, B., Ayuk, F., Wagner, E., Wulf, G., Marks, R., Penack, O., Schnetzke, U., Koenecke, C., von Bonin, M., Stelljes, M., Glass, B., Baldus, C. D., Vucinic, V., Mougiakakos, D., Topp, M., Schroers, R., . . . Bethge, W. A. (2023). Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: The GLA\/DRST experience. Bone Marrow Transplant, 58(2), 229\u2013232. https:\/\/doi.org\/10.1038\/s41409-022-01867-4","DOI":"10.1038\/s41409-022-01867-4"},{"issue":"10","key":"10227_CR113","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1016\/s2352-3026(22)00225-3","volume":"9","author":"S Ghorashian","year":"2022","unstructured":"Ghorashian, S., Jacoby, E., De Moerloose, B., Rives, S., Bonney, D., Shenton, G., Bader, P., Bodmer, N., Quintana, A. M., Herrero, B., Algeri, M., Locatelli, F., Vettenranta, K., Gonzalez, B., Attarbaschi, A., Harris, S., Bourquin, J. P., & Baruchel, A. (2022). Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: An international, multicentre, retrospective cohort study. The Lancet Haematology, 9(10), e766\u2013e775. https:\/\/doi.org\/10.1016\/s2352-3026(22)00225-3","journal-title":"The Lancet Haematology"},{"key":"10227_CR114","doi-asserted-by":"publisher","unstructured":"Moskop, A., Pommert, L., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., . . . Schultz, L. M. (2022). Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 6(14), 4251\u20134255. https:\/\/doi.org\/10.1182\/bloodadvances.2021006393","DOI":"10.1182\/bloodadvances.2021006393"},{"issue":"23","key":"10227_CR115","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","volume":"6","author":"AJ Faruqi","year":"2022","unstructured":"Faruqi, A. J., Ligon, J. A., Borgman, P., Steinberg, S. M., Foley, T., Little, L., Mackall, C. L., Lee, D. W., Fry, T. J., Shalabi, H., Brudno, J., Yates, B., Mikkilineni, L., Kochenderfer, J., & Shah, N. N. (2022). The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Advances, 6(23), 6040\u20136050. https:\/\/doi.org\/10.1182\/bloodadvances.2022007676","journal-title":"Blood Advances"},{"issue":"7","key":"10227_CR116","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1182\/bloodadvances.2020004018","volume":"5","author":"E Orgel","year":"2021","unstructured":"Orgel, E., Framson, C., Buxton, R., Kim, J., Li, G., Tucci, J., Freyer, D. R., Sun, W., Oberley, M. J., Dieli-Conwright, C., & Mittelman, S. D. (2021). Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: The IDEAL trial. Blood Advances, 5(7), 1853\u20131861. https:\/\/doi.org\/10.1182\/bloodadvances.2020004018","journal-title":"Blood Advances"},{"issue":"15","key":"10227_CR117","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1200\/jco.2006.07.7792","volume":"25","author":"AM Butturini","year":"2007","unstructured":"Butturini, A. M., Dorey, F. J., Lange, B. J., Henry, D. W., Gaynon, P. S., Fu, C., Franklin, J., Siegel, S. E., Seibel, N. L., Rogers, P. C., Sather, H., Trigg, M., Bleyer, W. A., & Carroll, W. L. (2007). Obesity and outcome in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology, 25(15), 2063\u20132069. https:\/\/doi.org\/10.1200\/jco.2006.07.7792","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10227_CR118","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s10552-014-0447-6","volume":"25","author":"QJ Leo","year":"2014","unstructured":"Leo, Q. J., Ollberding, N. J., Wilkens, L. R., Kolonel, L. N., Henderson, B. E., Le Marchand, L., & Maskarinec, G. (2014). Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: The Multiethnic Cohort study. Cancer Causes and Control, 25(11), 1449\u20131459. https:\/\/doi.org\/10.1007\/s10552-014-0447-6","journal-title":"Cancer Causes and Control"},{"issue":"7","key":"10227_CR119","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-021-00515-2","volume":"11","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn, K., Bansal, R., Khurana, A., Hathcock, M. A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., Johnston, P. B., Ansell, S. M., & Lin, Y. (2021). The impact of obesity and body weight on the outcome of patients with relapsed\/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer Journal, 11(7), 124. https:\/\/doi.org\/10.1038\/s41408-021-00515-2","journal-title":"Blood Cancer Journal"},{"issue":"8","key":"10227_CR120","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood, 106(8), 2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"8","key":"10227_CR121","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.bbmt.2015.04.004","volume":"21","author":"ML Sorror","year":"2015","unstructured":"Sorror, M. L., Logan, B. R., Zhu, X., Rizzo, J. D., Cooke, K. R., McCarthy, P. L., Ho, V. T., Horowitz, M. M., & Pasquini, M. C. (2015). Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: A Center for International Blood and Marrow Transplant Research study. Biology of Blood and Marrow Transplantation, 21(8), 1479\u20131487. https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.004","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"2, Supplement","key":"10227_CR122","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1016\/S2666-6367(23)00317-2","volume":"29","author":"SK Silbert","year":"2023","unstructured":"Silbert, S. K., Sarkisian, A., Steinberg, S. M., Yates, B., & Shah, N. N. (2023). 248 - Evaluating the prognostic utility of the hematopoietic cell transplantation comorbidity index (HCT-CI) in children and young adults with relapsed refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL) prior to CAR T-cell therapy. Transplantation and Cellular Therapy, 29(2, Supplement), S191. https:\/\/doi.org\/10.1016\/S2666-6367(23)00317-2","journal-title":"Transplantation and Cellular Therapy"},{"key":"10227_CR123","doi-asserted-by":"publisher","unstructured":"Greenbaum, U., Hashmi, H., Elsawy, M., Kim, S., Moskop, A., Awan, F. T., Farooq, U., Ganguly, S., Hematti, P., Jain, M. D., Kebriaei, P., Locke, F. L., Mead, E., Nishihori, T., Olson, A. L., Pennisi, M., Perales, M.-A., Ramakrishnan Geethakumari, P., Shouval, R., . . . Sorror, M. (2022). Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r\/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART). Blood, 140(Supplement 1), 4636\u20134638. https:\/\/doi.org\/10.1182\/blood-2022-169452","DOI":"10.1182\/blood-2022-169452"},{"key":"10227_CR124","doi-asserted-by":"publisher","unstructured":"Shouse, G., Kaempf, A., Gordon, M. J., Artz, A., Yashar, D., Sigmund, A. M., Smilnak, G., Bair, S. M., Mian, A., Fitzgerald, L. A., Bajwa, A., Jaglowski, S., Bailey, N., Shadman, M., Patel, K., Stephens, D. M., Kamdar, M., Hill, B. T., Gauthier, J., . . . Danilov, A. V. (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Advances, 7(14), 3516\u20133529. https:\/\/doi.org\/10.1182\/bloodadvances.2022009309","DOI":"10.1182\/bloodadvances.2022009309"},{"issue":"5","key":"10227_CR125","doi-asserted-by":"publisher","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K., Perez, A., Iacoboni, G., Penack, O., B\u00fccklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F. L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M. D., & Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. Journal for Immunotherapy of Cancer, 10(5), e004475. https:\/\/doi.org\/10.1136\/jitc-2021-004475","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"2","key":"10227_CR126","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jgo.2020.08.004","volume":"12","author":"JL Jaggers","year":"2021","unstructured":"Jaggers, J. L., Giri, S., Klepin, H. D., Wildes, T. M., Olin, R. L., Artz, A., Wall, S., Jaglowski, S., William, B., Benson, D. M., & Rosko, A. E. (2021). Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 12(2), 235\u2013238. https:\/\/doi.org\/10.1016\/j.jgo.2020.08.004","journal-title":"Journal of Geriatric Oncology"},{"issue":"1","key":"10227_CR127","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","volume":"12","author":"S Valade","year":"2022","unstructured":"Valade, S., Darmon, M., Zafrani, L., Mariotte, E., Lemiale, V., Bredin, S., Dumas, G., Boissel, N., Rabian, F., Baruchel, A., Madelaine, I., Larghero, J., Brignier, A., Lenglin\u00e9, E., Harel, S., Arnulf, B., Di Blasi, R., Thieblemont, C., & Azoulay, E. (2022). The use of ICU resources in CAR-T cell recipients: A hospital-wide study. Annals of Intensive Care, 12(1), 75. https:\/\/doi.org\/10.1186\/s13613-022-01036-2","journal-title":"Annals of Intensive Care"},{"issue":"20","key":"10227_CR128","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood.2022017579","volume":"141","author":"C Gutierrez","year":"2023","unstructured":"Gutierrez, C., Neilan, T. G., & Grover, N. S. (2023). How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood, 141(20), 2452\u20132459. https:\/\/doi.org\/10.1182\/blood.2022017579","journal-title":"Blood"},{"issue":"18","key":"10227_CR129","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J., Steingart, R. M., Mahmood, S. S., Schaffer, W. L., Perales, M. A., & Shouval, R. (2021). Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. Journal of the American College of Cardiology, 78(18), 1800\u20131813. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044","journal-title":"Journal of the American College of Cardiology"},{"key":"10227_CR130","doi-asserted-by":"publisher","unstructured":"Ragoonanan, D., Bhar, S., Mohan, G., Beltramo, F., Khazal, S. J., Hurley, C., Andersen, C., Margossian, S., Neelapu, S. S., Shpall, E., Gutierrez, C., Tewari, P., Shoberu, B., Talleur, A., McCall, D., Nunez, C., Cuglievan, B., Tambaro, F. P., Petropoulos, D., . . . Mahadeo, K. M. (2022). A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Frontiers in Oncology, 12, 1022901. https:\/\/doi.org\/10.3389\/fonc.2022.1022901","DOI":"10.3389\/fonc.2022.1022901"},{"issue":"2","key":"10227_CR131","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/ccm.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., Frey, N. V., Grupp, S. A., & Teachey, D. T. (2017). Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Critical Care Medicine, 45(2), e124\u2013e131. https:\/\/doi.org\/10.1097\/ccm.0000000000002053","journal-title":"Critical Care Medicine"},{"key":"10227_CR132","doi-asserted-by":"publisher","unstructured":"Azoulay, E., Shimabukuro-Vornhagen, A., Darmon, M., & von Bergwelt-Baildon, M. (2019). Critical care management of chimeric antigen receptor T cell-related toxicity. Be aware and prepared. American Journal of Respiratory and Critical Care Medicine, 200(1), 20\u201323. https:\/\/doi.org\/10.1164\/rccm.201810-1945ED","DOI":"10.1164\/rccm.201810-1945ED"},{"key":"10227_CR133","doi-asserted-by":"publisher","unstructured":"Azoulay, \u00c9., Castro, P., Maamar, A., Metaxa, V., de Moraes, A. G., Voigt, L., Wallet, F., Klouche, K., Picard, M., Moreau, A. S., Van De Louw, A., Seguin, A., Mokart, D., Chawla, S., Leroy, J., B\u00f6ll, B., Issa, N., Levy, B., Hemelaar, P., . . . Valade, S. (2021). Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study. Lancet Haematology, 8(5), e355-e364. https:\/\/doi.org\/10.1016\/s2352-3026(21)00060-0","DOI":"10.1016\/s2352-3026(21)00060-0"},{"issue":"1","key":"10227_CR134","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","volume":"14","author":"C Le Cacheux","year":"2024","unstructured":"Le Cacheux, C., Couturier, A., Sortais, C., Houot, R., P\u00e9r\u00e9, M., Gastinne, T., Seguin, A., Reignier, J., Lascarrou, J. B., Tadi\u00e9, J. M., Quelven, Q., & Canet, E. (2024). Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: A French multicentre cohort. Annals of Intensive Care, 14(1), 20. https:\/\/doi.org\/10.1186\/s13613-024-01247-9","journal-title":"Annals of Intensive Care"},{"issue":"7","key":"10227_CR135","doi-asserted-by":"publisher","first-page":"429.e421","DOI":"10.1016\/j.jtct.2023.03.019","volume":"29","author":"C De Philippis","year":"2023","unstructured":"De Philippis, C., Mannina, D., Giordano, L., Costantini, E., Marcheselli, S., Mariotti, J., Sarina, B., Taurino, D., Santoro, A., & Bramanti, S. (2023). Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma. Transplantation and Cellular Therapy, 29(7), 429.e421-429.e426. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.019","journal-title":"Transplantation and Cellular Therapy"},{"key":"10227_CR136","doi-asserted-by":"publisher","unstructured":"Gutierrez, C., Brown, A. R. T., Herr, M. M., Kadri, S. S., Hill, B., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K., Lin, Y., May, H. P., Gallo de Moraes, A., Maus, M. V., Frigault, M. J., Brudno, J. N., Athale, J., Shah, N. N., Kochenderfer, J. N., Dharshan, A., . . . Pastores, S. M. (2020). The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 58, 58\u201364. https:\/\/doi.org\/10.1016\/j.jcrc.2020.04.008","DOI":"10.1016\/j.jcrc.2020.04.008"},{"key":"10227_CR137","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jcrc.2017.01.007","volume":"39","author":"NK Rathi","year":"2017","unstructured":"Rathi, N. K., Haque, S. A., Nates, R., Kosturakis, A., Wang, H., Dong, W., Feng, L., Erfe, R. J., Guajardo, C., Withers, L., Finch, C., Price, K. J., & Nates, J. L. (2017). Noninvasivepositive pressure ventilation vsinvasive mechanical ventilation as first-line therapy for acute hypoxemic respiratory failure in cancer patients. Journal of Critical Care, 39, 56\u201361. https:\/\/doi.org\/10.1016\/j.jcrc.2017.01.007","journal-title":"Journal of Critical Care"},{"issue":"10","key":"10227_CR138","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1007\/s00134-010-1934-1","volume":"36","author":"V Squadrone","year":"2010","unstructured":"Squadrone, V., Massaia, M., Bruno, B., Marmont, F., Falda, M., Bagna, C., Bertone, S., Filippini, C., Slutsky, A. S., Vitolo, U., Boccadoro, M., & Ranieri, V. M. (2010). Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. Intensive Care Medicine, 36(10), 1666\u20131674. https:\/\/doi.org\/10.1007\/s00134-010-1934-1","journal-title":"Intensive Care Medicine"},{"issue":"4","key":"10227_CR139","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ncl.2020.08.001","volume":"38","author":"MW Ruff","year":"2020","unstructured":"Ruff, M. W., Siegler, E. L., & Kenderian, S. S. (2020). A concise review of neurologic complications associated with chimeric antigen receptor T-cell immunotherapy. Neurologic Clinics, 38(4), 953\u2013963. https:\/\/doi.org\/10.1016\/j.ncl.2020.08.001","journal-title":"Neurologic Clinics"},{"issue":"1","key":"10227_CR140","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13054-016-1294-5","volume":"20","author":"M Oddo","year":"2016","unstructured":"Oddo, M., Crippa, I. A., Mehta, S., Menon, D., Payen, J. F., Taccone, F. S., & Citerio, G. (2016). Optimizing sedation in patients with acute brain injury. Critical Care, 20(1), 128. https:\/\/doi.org\/10.1186\/s13054-016-1294-5","journal-title":"Critical Care"},{"key":"10227_CR141","doi-asserted-by":"publisher","unstructured":"Mahadeo, K. M., Khazal, S. J., Abdel-Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D., Steiner, M. E., Cheifetz, I. M., Lehmann, L. E., Mejia, R., Slopis, J. M., Bajwa, R., Kebriaei, P., Martin, P. L., Moffet, J., . . . Shpall, E. J. (2019). Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 16(1), 45\u201363. https:\/\/doi.org\/10.1038\/s41571-018-0075-2","DOI":"10.1038\/s41571-018-0075-2"},{"key":"10227_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown, B. D., Tambaro, F. P., Kohorst, M., Chi, L., Mahadeo, K. M., Tewari, P., Petropoulos, D., Slopis, J. M., Sadighi, Z., & Khazal, S. (2021). Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: Can we optimize early diagnosis? Frontiers in Oncology, 11, 634445. https:\/\/doi.org\/10.3389\/fonc.2021.634445","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10227_CR143","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/cji.0000000000000241","volume":"41","author":"H Shalabi","year":"2018","unstructured":"Shalabi, H., Wolters, P. L., Martin, S., Toledo-Tamula, M. A., Roderick, M. C., Struemph, K., Kane, E., Yates, B., Delbrook, C., Mackall, C. L., Lee, D. W., Fry, T. J., & Shah, N. N. (2018). Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. Journal of Immunotherapy, 41(7), 350\u2013358. https:\/\/doi.org\/10.1097\/cji.0000000000000241","journal-title":"Journal of Immunotherapy"},{"issue":"6","key":"10227_CR144","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2648.2008.04643.x","volume":"62","author":"N Power","year":"2008","unstructured":"Power, N., & Franck, L. (2008). Parent participation in the care of hospitalized children: A systematic review. Journal of Advanced Nursing, 62(6), 622\u2013641. https:\/\/doi.org\/10.1111\/j.1365-2648.2008.04643.x","journal-title":"Journal of Advanced Nursing"},{"issue":"1","key":"10227_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","volume":"30","author":"KO McNerney","year":"2024","unstructured":"McNerney, K. O., Hsieh, E. M., Shalabi, H., Epperly, R., Wolters, P. L., Hill, J. A., Gardner, R., Talleur, A. C., Shah, N. N., & Rossoff, J. (2024). INSPIRED Symposium part 3: Prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities. Transplant Cell Ther, 30(1), 38\u201355. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.006","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10227_CR146","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/02692163221138880","volume":"37","author":"CL Stenson","year":"2023","unstructured":"Stenson, C. L., Vidrine, J., Dewhurst, F., Osborne, W., Menne, T., & Stocker, R. (2023). A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams. Palliative Medicine, 37(2), 215\u2013220. https:\/\/doi.org\/10.1177\/02692163221138880","journal-title":"Palliative Medicine"},{"issue":"12","key":"10227_CR147","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000802","volume":"6","author":"F Efficace","year":"2022","unstructured":"Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E., Luppi, M., & Platzbecker, U. (2022). Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: A scoping review. Hemasphere, 6(12), e802. https:\/\/doi.org\/10.1097\/hs9.0000000000000802","journal-title":"Hemasphere"},{"issue":"14","key":"10227_CR148","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","volume":"7","author":"PC Johnson","year":"2023","unstructured":"Johnson, P. C., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Lavoie, M. W., Vaughn, D., Karpinski, K., & El-Jawahri, A. (2023). Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 7(14), 3541\u20133550. https:\/\/doi.org\/10.1182\/bloodadvances.2022009117","journal-title":"Blood Advances"},{"issue":"11","key":"10227_CR149","doi-asserted-by":"publisher","first-page":"930.e931","DOI":"10.1016\/j.jtct.2021.07.007","volume":"27","author":"XS Wang","year":"2021","unstructured":"Wang, X. S., Srour, S. A., Whisenant, M., Subbiah, I. M., Chen, T. H., Ponce, D., Gonzalez, A. G., Kamal, M., Mendoza, T., Cleland, C. S., Kebriaei, P., Neelapu, S. S., Rezvani, K., Ahmed, S., & Shpall, E. (2021). Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther, 27(11), 930.e931-930.e910. https:\/\/doi.org\/10.1016\/j.jtct.2021.07.007","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10227_CR150","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","volume":"28","author":"S Sidana","year":"2022","unstructured":"Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., Burtis, M., Warsame, R., Paludo, J., Gertz, M. A., Dispenzieri, A., Ansell, S. M., Rajkumar, S. V., Yost, K., Bennani, N., Lin, Y., & Kumar, S. (2022). Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant. Transplantation and Cellular Therapy, 28(8), 473\u2013482. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.004","journal-title":"Transplantation and Cellular Therapy"},{"issue":"4","key":"10227_CR151","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/bjh.18677","volume":"201","author":"XS Wang","year":"2023","unstructured":"Wang, X. S., Srour, S. A., Mendoza, T., Whisenant, M., Subbiah, I., Gonzalez, E., Kamal, M., Shen, S. E., Cleeland, C., Kebriaei, P., Rezvani, K., Neelapu, S., Ahmed, S., & Shpall, E. (2023). Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. British Journal of Haematology, 201(4), 738\u2013746. https:\/\/doi.org\/10.1111\/bjh.18677","journal-title":"British Journal of Haematology"},{"key":"10227_CR152","doi-asserted-by":"publisher","unstructured":"Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H., Buechner, J., De Moerloose, B., Davis, K. L., Nemecek, E., Driscoll, T., Mechinaud, F., Boissel, N., Rives, S., Bader, P., Peters, C., Sabnis, H. S., Grupp, S. A., Yanik, G. A., . . . Harris, A. C. (2019). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial. The Lancet Oncology, 20(12), 1710\u20131718. https:\/\/doi.org\/10.1016\/s1470-2045(19)30493-0","DOI":"10.1016\/s1470-2045(19)30493-0"},{"issue":"8","key":"10227_CR153","doi-asserted-by":"publisher","first-page":"e006959","DOI":"10.1136\/jitc-2023-006959","volume":"11","author":"NP Tschernia","year":"2023","unstructured":"Tschernia, N. P., Heiling, H., Deal, A. M., Cheng, C., Babinec, C., Gonzalez, M., Morrison, J. K., Dittus, C., Dotti, G., Beaven, A. W., Serody, J. S., Wood, W. A., Savoldo, B., & Grover, N. S. (2023). Patient-reported outcomes in CD30-directed CAR-T cells against relapsed\/refractory CD30+ lymphomas. Journal for Immunotherapy of Cancer, 11(8), e006959. https:\/\/doi.org\/10.1136\/jitc-2023-006959","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"4","key":"10227_CR154","doi-asserted-by":"publisher","first-page":"452.e451","DOI":"10.1016\/j.jtct.2024.01.063","volume":"30","author":"A Barata","year":"2024","unstructured":"Barata, A., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Nelson, A. M., Yang, D., Karpinski, K., Holmbeck, K., Farnam, E., Frigault, M., Johnson, P. C., & El-Jawahri, A. (2024). Quality of life and prognostic awareness in caregivers of patients receiving chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 30(4), 452.e451-452.e411. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.063","journal-title":"Transplantation and Cellular Therapy"},{"issue":"11","key":"10227_CR155","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/jco.2013.51.5981","volume":"32","author":"J Wolfe","year":"2014","unstructured":"Wolfe, J., Orellana, L., Cook, E. F., Ullrich, C., Kang, T., Geyer, J. R., Feudtner, C., Weeks, J. C., & Dussel, V. (2014). Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: Results from the PediQUEST randomized controlled trial. Journal of Clinical Oncology, 32(11), 1119\u20131126. https:\/\/doi.org\/10.1200\/jco.2013.51.5981","journal-title":"Journal of Clinical Oncology"},{"key":"10227_CR156","doi-asserted-by":"publisher","first-page":"e50993","DOI":"10.2196\/50993","volume":"12","author":"JS Lai","year":"2023","unstructured":"Lai, J. S., Jensen, S. E., Peipert, J. D., Mitchell, S. A., Garcia, S. F., Cella, D., Goldman, S., & Lenzen, A. (2023). Using IT to improve outcomes for children living with cancer (SyMon-SAYS): Protocol for a single-institution waitlist randomized controlled trial. JMIR Research Protocols, 12, e50993. https:\/\/doi.org\/10.2196\/50993","journal-title":"JMIR Research Protocols"},{"key":"10227_CR157","doi-asserted-by":"publisher","unstructured":"Velikova, G., Absolom, K., Hewison, J., Holch, P., Warrington, L., Avery, K., Richards, H., Blazeby, J., Dawkins, B., Hulme, C., Carter, R., Glidewell, L., Henry, A., Franks, K., Hall, G., Davidson, S., Henry, K., Morris, C., Conner, M., . . . Brown, J. (2022). Programme grants for applied research. In Electronic self-reporting of adverse events for patients undergoing cancer treatment: The eRAPID research programme including two RCTs. NIHR Journals Library. Copyright \u00a9 2022 Velikova et al. This work was produced by Velikova et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https:\/\/creativecommons.org\/licenses\/by\/4.0\/. For attribution the title, original author(s), the publication source \u2013 NIHR Journals Library, and the DOI of the publication must be cited. https:\/\/doi.org\/10.3310\/fdde8516","DOI":"10.3310\/fdde8516"},{"issue":"5","key":"10227_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28249","volume":"67","author":"A Steineck","year":"2020","unstructured":"Steineck, A., Wiener, L., Mack, J. W., Shah, N. N., Summers, C., & Rosenberg, A. R. (2020). Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy. Pediatric Blood & Cancer, 67(5), e28249. https:\/\/doi.org\/10.1002\/pbc.28249","journal-title":"Pediatric Blood & Cancer"},{"issue":"3","key":"10227_CR159","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/spc.0000000000000657","volume":"17","author":"D Springell","year":"2023","unstructured":"Springell, D., O\u2019Reilly, M., & Roddie, C. (2023). Supportive care for chimeric antigen receptor T-cell patients. Current Opinion in Supportive and Palliative Care, 17(3), 231\u2013239. https:\/\/doi.org\/10.1097\/spc.0000000000000657","journal-title":"Current Opinion in Supportive and Palliative Care"},{"key":"10227_CR160","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff, E. R. S., Kelkar, A. H., Russler-Germain, D. A., Tessema, F. A., Raymakers, A. J. N., Feldman, W. B., & Kesselheim, A. S. (2023). High cost of chimeric antigen receptor T-cells: Challenges and solutions. American Society of Clinical Oncology Educational Book, 43, e397912. https:\/\/doi.org\/10.1200\/edbk_397912","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"2","key":"10227_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1980","volume":"7","author":"A Hoover","year":"2024","unstructured":"Hoover, A., Reimche, P., Watson, D., Tanner, L., Gilchrist, L., Finch, M., Messinger, Y. H., & Turcotte, L. M. (2024). Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis. Cancer Rep (Hoboken), 7(2), e1980. https:\/\/doi.org\/10.1002\/cnr2.1980","journal-title":"Cancer Rep (Hoboken)"},{"issue":"7","key":"10227_CR162","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","volume":"28","author":"N Ahmed","year":"2022","unstructured":"Ahmed, N., Shahzad, M., Shippey, E., Bansal, R., Mushtaq, M. U., Mahmoudjafari, Z., Faisal, M. S., Hoffmann, M., Abdallah, A. O., Divine, C., Hamadani, M., McGuirk, J., & Shune, L. (2022). Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplantation and Cellular Therapy, 28(7), 358\u2013364. https:\/\/doi.org\/10.1016\/j.jtct.2022.04.008","journal-title":"Transplantation and Cellular Therapy"},{"issue":"8005","key":"10227_CR163","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty, S. (2024). Cutting-edge CAR-T cancer therapy is now made in India - At one-tenth the cost. Nature, 627(8005), 709\u2013710. https:\/\/doi.org\/10.1038\/d41586-024-00809-y","journal-title":"Nature"},{"issue":"2","key":"10227_CR164","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"HK Palani","year":"2023","unstructured":"Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., Lionel, S. A., Selvarajan, S., Korula, A., Abraham, A., George, B., Adair, J. E., Orentas, R., Dropulic, B., & Mathews, V. (2023). Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: Real-world experience and cost analysis in India. Bone Marrow Transplantation, 58(2), 160\u2013167. https:\/\/doi.org\/10.1038\/s41409-022-01866-5","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10227_CR165","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12896-019-0537-3","volume":"19","author":"A Juillerat","year":"2019","unstructured":"Juillerat, A., Tkach, D., Busser, B. W., Temburni, S., Valton, J., Duclert, A., Poirot, L., Depil, S., & Duchateau, P. (2019). Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnology, 19(1), 44. https:\/\/doi.org\/10.1186\/s12896-019-0537-3","journal-title":"BMC Biotechnology"},{"issue":"6258","key":"10227_CR166","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 350(6258), aab4077. https:\/\/doi.org\/10.1126\/science.aab4077","journal-title":"Science"},{"key":"10227_CR167","doi-asserted-by":"publisher","first-page":"18950","DOI":"10.1038\/srep18950","volume":"6","author":"A Juillerat","year":"2016","unstructured":"Juillerat, A., Marechal, A., Filhol, J. M., Valton, J., Duclert, A., Poirot, L., & Duchateau, P. (2016). Design of chimeric antigen receptors with integrated controllable transient functions. Science and Reports, 6, 18950. https:\/\/doi.org\/10.1038\/srep18950","journal-title":"Science and Reports"},{"key":"10227_CR168","doi-asserted-by":"publisher","unstructured":"Appelbaum, J., Price, A. E., Oda, K., Zhang, J., Leung, W. H., Tampella, G., Xia, D., So, P. P., Hilton, S. K., Evandy, C., Sarkar, S., Martin, U., Krostag, A. R., Leonardi, M., Zak, D. E., Logan, R., Lewis, P., Franke-Welch, S., Ngwenyama, N., . . . Jensen, M. C. (2024). Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. Journal of Clinical Investigation, 134(9). https:\/\/doi.org\/10.1172\/jci162593","DOI":"10.1172\/jci162593"},{"key":"10227_CR169","doi-asserted-by":"publisher","unstructured":"Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., Duan, P., Lin, Y., Zheng, W., Wang, X., Lin, N., Tu, M., Xie, Y., Zhang, C., Liu, W., . . . Chen, S. Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine, 25(6), 947\u2013953. https:\/\/doi.org\/10.1038\/s41591-019-0421-7","DOI":"10.1038\/s41591-019-0421-7"},{"key":"10227_CR170","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","volume":"9","author":"J Fisher","year":"2018","unstructured":"Fisher, J., & Anderson, J. (2018). Engineering approaches in human gamma delta T cells for cancer immunotherapy. Frontiers in Immunology, 9, 1409. https:\/\/doi.org\/10.3389\/fimmu.2018.01409","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10227_CR171","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ymthe.2017.03.002","volume":"25","author":"J Fisher","year":"2017","unstructured":"Fisher, J., Abramowski, P., Wisidagamage Don, N. D., Flutter, B., Capsomidis, A., Cheung, G. W., Gustafsson, K., & Anderson, J. (2017). Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Molecular Therapy, 25(5), 1234\u20131247. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.002","journal-title":"Molecular Therapy"},{"key":"10227_CR172","doi-asserted-by":"publisher","unstructured":"Kim, M. Y., Yu, K. R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T. H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., Kozlowski, M. S., Cummins, K. D., Shan, X., Shestov, M., Bagg, A., Morrissette, J. J. D., Sekhri, P., Lazzarotto, C. R., Calvo, K. R., . . . Gill, S. (2018). Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell, 173(6), 1439\u20131453.e1419. https:\/\/doi.org\/10.1016\/j.cell.2018.05.013","DOI":"10.1016\/j.cell.2018.05.013"},{"issue":"24","key":"10227_CR173","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood.2021014860","volume":"139","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., Zhao, Y. Z., Ma, H. H., Wang, D., Cui, L., Li, W. J., Wei, A., Wang, C. J., Wang, T. Y., Li, Z. G., & Zhang, R. (2022). A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood, 139(24), 3493\u20133504. https:\/\/doi.org\/10.1182\/blood.2021014860","journal-title":"Blood"},{"issue":"5","key":"10227_CR174","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang, J., Wang, Y., Wu, L., Wang, X., Jin, Z., Gao, Z., & Wang, Z. (2020). Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica, 105(5), e210\u2013e212. https:\/\/doi.org\/10.3324\/haematol.2019.222471","journal-title":"Haematologica"},{"issue":"4","key":"10227_CR175","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"J Wang","year":"2021","unstructured":"Wang, J., Zhang, R., Wu, X., Li, F., Yang, H., Liu, L., Guo, H., Zhang, X., Mai, H., Li, H., & Wang, Z. (2021). Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: A single-arm, multicentre, phase 2 trial. British Journal of Haematology, 193(4), 761\u2013768. https:\/\/doi.org\/10.1111\/bjh.17331","journal-title":"British Journal of Haematology"},{"issue":"25","key":"10227_CR176","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten, E., Horne, A., Aric\u00f3, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., Ishii, E., Janka, G., Ladisch, S., Lehmberg, K., McClain, K. L., Minkov, M., Montgomery, S., Nanduri, V., Rosso, D., & Henter, J. I. (2017). Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-term results of the cooperative HLH-2004 study. Blood, 130(25), 2728\u20132738. https:\/\/doi.org\/10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"issue":"13","key":"10227_CR177","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R. T., Do, B., Rodriguez, M. A., Nair, R., Shpall, E. J., Green, M. R., Neelapu, S. S., & Westin, J. R. (2020). Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Advances, 4(13), 3123\u20133127. https:\/\/doi.org\/10.1182\/bloodadvances.2020002328","journal-title":"Blood Advances"},{"issue":"Supplement 1","key":"10227_CR178","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1182\/blood-2021-153987","volume":"138","author":"SS Kenderian","year":"2021","unstructured":"Kenderian, S. S., Durrant, C., Chappell, D., Ahmed, O., & Kilcoyne, A. (2021). A phase 2\/3 randomized, placebo-controlled, open-label, multi-center trial of lenzilumab to improve the safety and efficacy of CAR-T cell therapy in adults with relapsed or refractory large B-cell lymphoma (The SHIELD Study). Blood, 138(Supplement 1), 1758\u20131758. https:\/\/doi.org\/10.1182\/blood-2021-153987","journal-title":"Blood"},{"issue":"7","key":"10227_CR179","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G., Dahi, P., Lin, R. J., Scordo, M., Perales, M. A., Shouval, R., Tomas, A. A., Cathcart, E., Mead, E., Santomasso, B., Holodny, A., Brentjens, R. J., Riviere, I., & Sadelain, M. (2023). CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results. Nature Medicine, 29(7), 1710\u20131717. https:\/\/doi.org\/10.1038\/s41591-023-02404-6","journal-title":"Nature Medicine"},{"issue":"Supplement 1","key":"10227_CR180","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1182\/blood-2022-169809","volume":"140","author":"S Patel","year":"2022","unstructured":"Patel, S., Cenin, D., Corrigan, D., Hamilton, B. K., Kalaycio, M., Sobecks, R. M., Anwer, F., Khouri, J., Dean, R. M., Winter, A., Jagadeesh, D., Pohlman, B., Hill, B. T., Sauter, C. S., & Caimi, P. F. (2022). Siltuximab for first-line treatment of cytokine release syndrome: A response to the national shortage of tocilizumab. Blood, 140(Supplement 1), 5073\u20135074. https:\/\/doi.org\/10.1182\/blood-2022-169809","journal-title":"Blood"},{"issue":"Supplement 1","key":"10227_CR181","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1182\/blood-2023-179620","volume":"142","author":"AK Bajwa","year":"2023","unstructured":"Bajwa, A. K., Zhao, Q., Geer, M. J., Mian, A., Lin, C., Frame, D., Westholder, J., Tossey, J., Ghosh, M., Galal, A., Ahmed, N., Maakaron, J. E., Denlinger, N., de Lima, M., Epperla, N., Caimi, P. F., & Voorhees, T. (2023). Efficacy of siltuximab for chimeric antigen receptor T-cell therapy toxicities - A multicenter retrospective analysis. Blood, 142(Supplement 1), 4502\u20134502. https:\/\/doi.org\/10.1182\/blood-2023-179620","journal-title":"Blood"},{"issue":"9","key":"10227_CR182","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., Heike, T., & Nakahata, T. (2002). NOD\/SCID\/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood, 100(9), 3175\u20133182. https:\/\/doi.org\/10.1182\/blood-2001-12-0207","journal-title":"Blood"},{"issue":"6","key":"10227_CR183","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/ijms23063154","volume":"23","author":"X Si","year":"2022","unstructured":"Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022). Preclinical evaluation of CAR T cell function: In vitro and in vivo models. International Journal of Molecular Sciences, 23(6), 3154. https:\/\/doi.org\/10.3390\/ijms23063154","journal-title":"International Journal of Molecular Sciences"},{"key":"10227_CR184","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omtm.2022.08.008","volume":"27","author":"BB Duncan","year":"2022","unstructured":"Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022). Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy - Methods & Clinical Development, 27, 17\u201331. https:\/\/doi.org\/10.1016\/j.omtm.2022.08.008","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"9","key":"10227_CR185","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","volume":"191","author":"SJ van der Stegen","year":"2013","unstructured":"van der Stegen, S. J., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., Jeannon, J. P., Parente-Pereira, A. C., & Maher, J. (2013). Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: Identifying a window of therapeutic opportunity? The Journal of Immunology, 191(9), 4589\u20134598. https:\/\/doi.org\/10.4049\/jimmunol.1301523","journal-title":"The Journal of Immunology"},{"issue":"6","key":"10227_CR186","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018). CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine, 24(6), 731\u2013738. https:\/\/doi.org\/10.1038\/s41591-018-0041-7","journal-title":"Nature Medicine"},{"issue":"11","key":"10227_CR187","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.Cd-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson, B., Li, Y., Lin, Y., Liu, E. T., & Patnaik, A. (2018). Mouse models for cancer immunotherapy research. Cancer Discovery, 8(11), 1358\u20131365. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0044","journal-title":"Cancer Discovery"},{"key":"10227_CR188","doi-asserted-by":"publisher","unstructured":"Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S., Ombrello, A. K., Dulau-Florea, A., Eckhaus, M. A., Shalabi, H., Yates, B., Lichtenstein, D. A., Zimmermann, V. S., Kondo, T., Shern, J. F., Young, H. A., Taylor, N., . . . Fry, T. J. (2020). Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. Journal of Clinical Investigation, 130(10), 5425\u20135443. https:\/\/doi.org\/10.1172\/jci130059","DOI":"10.1172\/jci130059"},{"issue":"6","key":"10227_CR189","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ymthe.2018.04.006","volume":"26","author":"CA Pennell","year":"2018","unstructured":"Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis-Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M., Thangavelu, G., Campbell, H. M., Storlie, M. D., Refaeli, Y., Furlan, S. N., Jensen, M. C., Kean, L. S., Miller, J. S., Tolar, J., Osborn, M. J., & Blazar, B. R. (2018). Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice. Molecular Therapy, 26(6), 1423\u20131434. https:\/\/doi.org\/10.1016\/j.ymthe.2018.04.006","journal-title":"Molecular Therapy"},{"issue":"6","key":"10227_CR190","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., Traversari, C., Bordignon, C., Ciceri, F., Ostuni, R., Bonini, C., Casucci, M., & Bondanza, A. (2018). Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 24(6), 739\u2013748. https:\/\/doi.org\/10.1038\/s41591-018-0036-4","journal-title":"Nature Medicine"},{"key":"10227_CR191","doi-asserted-by":"publisher","unstructured":"Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., Yu, A., Zheng, H., Furlan, S. N., Hunt, D. J., Hoglund, V., Finney, O., Brakke, H., Blazar, B. R., Berger, C., . . . Jensen, M. C. (2018). Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discovery, 8(6), 750\u2013763. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-1368","DOI":"10.1158\/2159-8290.Cd-17-1368"},{"issue":"2","key":"10227_CR192","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/2326-6066.Cir-14-0163","volume":"3","author":"C Berger","year":"2015","unstructured":"Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015). Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research, 3(2), 206\u2013216. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0163","journal-title":"Cancer Immunology Research"},{"issue":"6","key":"10227_CR193","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1291","volume":"10","author":"S Yagyu","year":"2021","unstructured":"Yagyu, S., Mochizuki, H., Yamashima, K., Kubo, H., Saito, S., Tanaka, M., Sakamoto, K., Shimoi, A., & Nakazawa, Y. (2021). A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. Clin Transl Immunology, 10(6), e1291. https:\/\/doi.org\/10.1002\/cti2.1291","journal-title":"Clin Transl Immunology"},{"issue":"3","key":"10227_CR194","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17(3), 147\u2013167. https:\/\/doi.org\/10.1038\/s41571-019-0297-y","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"7","key":"10227_CR195","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.tibtech.2021.12.009","volume":"40","author":"ER Vander Mause","year":"2022","unstructured":"Vander Mause, E. R., Atanackovic, D., Lim, C. S., & Luetkens, T. (2022). Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. Trends in Biotechnology, 40(7), 875\u2013890. https:\/\/doi.org\/10.1016\/j.tibtech.2021.12.009","journal-title":"Trends in Biotechnology"},{"issue":"17","key":"10227_CR196","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.Can-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., Lee, D. A., Heimberger, A. B., Champlin, R. E., & Cooper, L. J. (2015). Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Research, 75(17), 3505\u20133518. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0139","journal-title":"Cancer Research"},{"issue":"25","key":"10227_CR197","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","volume":"6","author":"DG Song","year":"2015","unstructured":"Song, D. G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J., Jr. (2015). A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget, 6(25), 21533\u201321546. https:\/\/doi.org\/10.18632\/oncotarget.4071","journal-title":"Oncotarget"},{"issue":"17","key":"10227_CR198","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.Can-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., Zhou, L., Loew, A., Young, R. M., June, C. H., & Zhao, Y. (2015). Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Research, 75(17), 3596\u20133607. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0159","journal-title":"Cancer Research"},{"issue":"12","key":"10227_CR199","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","volume":"173","author":"M Chmielewski","year":"2004","unstructured":"Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004). T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. The Journal of Immunology, 173(12), 7647\u20137653. https:\/\/doi.org\/10.4049\/jimmunol.173.12.7647","journal-title":"The Journal of Immunology"},{"key":"10227_CR200","doi-asserted-by":"publisher","unstructured":"Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P. A., Mekkaoui, L., Cheung, G. W., Pinner, D., Chu, J., . . . Amrolia, P. J. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9), 1408\u20131414. https:\/\/doi.org\/10.1038\/s41591-019-0549-5","DOI":"10.1038\/s41591-019-0549-5"},{"key":"10227_CR201","doi-asserted-by":"publisher","unstructured":"Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadinanos-Garai, A., Vispute, K., Bosshard-Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., Hartley, J. A., Spanswick, V., Lowe, H., Popova, B., Clifton-Hadley, L., Wheeler, G., Olejnik, J., Bloor, A., Irvine, D., . . . Peggs, K. S. (2021). Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 39(30), 3352\u20133363. https:\/\/doi.org\/10.1200\/jco.21.00917","DOI":"10.1200\/jco.21.00917"},{"key":"10227_CR202","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J. C., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., Angelos, M., Guruprasad, P., Cohen, I., Ugwuanyi, O., Lee, Y. G., Pajarillo, R., Cho, J. H., Carturan, A., Paruzzo, L., . . . Ruella, M. (2023). Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: A first-in-human study. Molecular Cancer, 22(1), 200. https:\/\/doi.org\/10.1186\/s12943-023-01886-9","DOI":"10.1186\/s12943-023-01886-9"},{"issue":"5","key":"10227_CR203","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","volume":"11","author":"LM Whilding","year":"2019","unstructured":"Whilding, L. M., Halim, L., Draper, B., Parente-Pereira, A. C., Zabinski, T., Davies, D. M., & Maher, J. (2019). CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel), 11(5), 674. https:\/\/doi.org\/10.3390\/cancers11050674","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10227_CR204","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.Cd-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I., & Sadelain, M. (2023). Programming CAR T cell tumor recognition: Tuned antigen sensing and logic gating. Cancer Discovery, 13(4), 829\u2013843. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0101","journal-title":"Cancer Discovery"},{"issue":"7952","key":"10227_CR205","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W. J., Lareau, C., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., Yin, Y., Klysz, D., Xu, P., de la Serna, E. L., Dunn, A. R., Satpathy, A. T., Mackall, C. L., & Majzner, R. G. (2023). Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 615(7952), 507\u2013516. https:\/\/doi.org\/10.1038\/s41586-023-05778-2","journal-title":"Nature"},{"issue":"1","key":"10227_CR206","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.Cir-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J., Jr. (2013). Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunology Research, 1(1), 43\u201353. https:\/\/doi.org\/10.1158\/2326-6066.Cir-13-0008","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10227_CR207","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 31(1), 71\u201375. https:\/\/doi.org\/10.1038\/nbt.2459","journal-title":"Nature Biotechnology"},{"issue":"5","key":"10227_CR208","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J., Pereira, A. C., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of Clinical Immunology, 32(5), 1059\u20131070. https:\/\/doi.org\/10.1007\/s10875-012-9689-9","journal-title":"Journal of Clinical Immunology"},{"key":"10227_CR209","doi-asserted-by":"publisher","unstructured":"Katsarou, A., Sj\u00f6strand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., Patankar, Y. R., Merino, E., Reijmers, R. M., Frerichs, K. A., Yuan, H., de Bruijn, J., Stroopinsky, D., Avigan, D., van de Donk, N., . . . Themeli, M. (2021). Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 13(623), eabh1962. https:\/\/doi.org\/10.1126\/scitranslmed.abh1962","DOI":"10.1126\/scitranslmed.abh1962"},{"issue":"6","key":"10227_CR210","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood.2023021054","volume":"143","author":"T Dao","year":"2024","unstructured":"Dao, T., Xiong, G., Mun, S. S., Meyerberg, J., Korontsvit, T., Xiang, J., Cui, Z., Chang, A. Y., Jarvis, C., Cai, W., Luo, H., Pierson, A., Daniyan, A., Yoo, S., Takao, S., Kharas, M., Kentsis, A., Liu, C., & Scheinberg, D. A. (2024). A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood, 143(6), 507\u2013521. https:\/\/doi.org\/10.1182\/blood.2023021054","journal-title":"Blood"},{"issue":"4","key":"10227_CR211","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016). Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 164(4), 770\u2013779. https:\/\/doi.org\/10.1016\/j.cell.2016.01.011","journal-title":"Cell"},{"issue":"3","key":"10227_CR212","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., & Riddell, S. R. (2019). Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell, 35(3), 489-503.e488. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.003","journal-title":"Cancer Cell"},{"issue":"4","key":"10227_CR213","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell, 164(4), 780\u2013791. https:\/\/doi.org\/10.1016\/j.cell.2016.01.012","journal-title":"Cell"},{"key":"10227_CR214","doi-asserted-by":"publisher","unstructured":"Choe, J. H., Watchmaker, P. B., Simic, M. S., Gilbert, R. D., Li, A. W., Krasnow, N. A., Downey, K. M., Yu, W., Carrera, D. A., Celli, A., Cho, J., Briones, J. D., Duecker, J. M., Goretsky, Y. E., Dannenfelser, R., Cardarelli, L., Troyanskaya, O., Sidhu, S. S., Roybal, K. T., . . . Lim, W. A. (2021). SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Medicine, 13(591). https:\/\/doi.org\/10.1126\/scitranslmed.abe7378","DOI":"10.1126\/scitranslmed.abe7378"},{"issue":"2","key":"10227_CR215","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167(2), 419-432.e416. https:\/\/doi.org\/10.1016\/j.cell.2016.09.011","journal-title":"Cell"},{"issue":"591","key":"10227_CR216","doi-asserted-by":"publisher","first-page":"8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J. M., Alavi, J., Perry, N., Montgomery, G., Liu, B., & Roybal, K. T. (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Science Translational Medicine, 13(591), 8836. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836","journal-title":"Science Translational Medicine"},{"issue":"6","key":"10227_CR217","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2643-3230.Bcd-20-0208","volume":"2","author":"RM Richards","year":"2021","unstructured":"Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A., Sotillo, E., Daugaard, M., Oo, H. Z., Liu, J., Hong, W. J., Sorensen, P. H., Chang, H. Y., Satpathy, A. T., Majzner, R. G., Majeti, R., & Mackall, C. L. (2021). NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discovery, 2(6), 648\u2013665. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-20-0208","journal-title":"Blood Cancer Discovery"},{"issue":"215","key":"10227_CR218","doi-asserted-by":"publisher","first-page":"215ra17","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M., & Sadelain, M. (2013). PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5(215), 215ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3006597","journal-title":"Science Translational Medicine"},{"issue":"6","key":"10227_CR219","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/hgtb.2012.050","volume":"23","author":"V Marin","year":"2012","unstructured":"Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., & Pule, M. (2012). Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods, 23(6), 376\u2013386. https:\/\/doi.org\/10.1089\/hgtb.2012.050","journal-title":"Hum Gene Ther Methods"},{"key":"10227_CR220","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","volume":"74","author":"AC Sahillioglu","year":"2022","unstructured":"Sahillioglu, A. C., & Schumacher, T. N. (2022). Safety switches for adoptive cell therapy. Current Opinion in Immunology, 74, 190\u2013198. https:\/\/doi.org\/10.1016\/j.coi.2021.07.002","journal-title":"Current Opinion in Immunology"},{"key":"10227_CR221","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fphar.2014.00254","volume":"5","author":"BS Jones","year":"2014","unstructured":"Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014). Improving the safety of cell therapy products by suicide gene transfer. Frontiers in Pharmacology, 5, 254. https:\/\/doi.org\/10.3389\/fphar.2014.00254","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10227_CR222","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/10430340460732463","volume":"15","author":"M Serafini","year":"2004","unstructured":"Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004). Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Human Gene Therapy, 15(1), 63\u201376. https:\/\/doi.org\/10.1089\/10430340460732463","journal-title":"Human Gene Therapy"},{"issue":"9","key":"10227_CR223","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","volume":"94","author":"M Griffioen","year":"2009","unstructured":"Griffioen, M., van Egmond, E. H., Kester, M. G., Willemze, R., Falkenburg, J. H., & Heemskerk, M. H. (2009). Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica, 94(9), 1316\u20131320. https:\/\/doi.org\/10.3324\/haematol.2008.001677","journal-title":"Haematologica"},{"issue":"8","key":"10227_CR224","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., Quezada, S. A., Peggs, K. S., & Pule, M. (2014). A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood, 124(8), 1277\u20131287. https:\/\/doi.org\/10.1182\/blood-2014-01-545020","journal-title":"Blood"},{"issue":"5","key":"10227_CR225","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X., Chang, W. C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood, 118(5), 1255\u20131263. https:\/\/doi.org\/10.1182\/blood-2011-02-337360","journal-title":"Blood"},{"issue":"11","key":"10227_CR226","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/jci84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz, P. J., Fr\u00e4\u00dfle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., & Busch, D. H. (2016). Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of Clinical Investigation, 126(11), 4262\u20134272. https:\/\/doi.org\/10.1172\/jci84813","journal-title":"The Journal of Clinical Investigation"},{"key":"10227_CR227","doi-asserted-by":"publisher","unstructured":"Shabaneh, T. B., Moffett, H. F., Stull, S. M., Derezes, T., Tait, L. J., Park, S., Riddell, S. R., & Lajoie, M. J. (2022). Safety switch optimization enhances antibody-mediated elimination of CAR T cells [Original Research]. Frontiers in Molecular Medicine, 2. https:\/\/doi.org\/10.3389\/fmmed.2022.1026474","DOI":"10.3389\/fmmed.2022.1026474"},{"issue":"9","key":"10227_CR228","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/13543776.2016.1211640","volume":"26","author":"SA Navarro","year":"2016","unstructured":"Navarro, S. A., Carrillo, E., Gri\u00f1\u00e1n-Lis\u00f3n, C., Mart\u00edn, A., Per\u00e1n, M., Marchal, J. A., & Boulaiz, H. (2016). Cancer suicide gene therapy: A patent review. Expert Opinion on Therapeutic Patents, 26(9), 1095\u20131104. https:\/\/doi.org\/10.1080\/13543776.2016.1211640","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"11","key":"10227_CR229","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.exphem.2016.07.011","volume":"44","author":"X Zhou","year":"2016","unstructured":"Zhou, X., & Brenner, M. K. (2016). Improving the safety of T-cell therapies using an inducible caspase-9 gene. Experimental Hematology, 44(11), 1013\u20131019. https:\/\/doi.org\/10.1016\/j.exphem.2016.07.011","journal-title":"Experimental Hematology"},{"issue":"5","key":"10227_CR230","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.ymthe.2018.03.001","volume":"26","author":"M Stavrou","year":"2018","unstructured":"Stavrou, M., Philip, B., Traynor-White, C., Davis, C. G., Onuoha, S., Cordoba, S., Thomas, S., & Pule, M. (2018). A rapamycin-activated caspase 9-based suicide gene. Molecular Therapy, 26(5), 1266\u20131276. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.001","journal-title":"Molecular Therapy"},{"issue":"8","key":"10227_CR231","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","volume":"13","author":"SK Tey","year":"2007","unstructured":"Tey, S. K., Dotti, G., Rooney, C. M., Heslop, H. E., & Brenner, M. K. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biology of Blood and Marrow Transplantation, 13(8), 913\u2013924. https:\/\/doi.org\/10.1016\/j.bbmt.2007.04.005","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"18","key":"10227_CR232","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., Liu, H., Cruz, C. R., Savoldo, B., Gee, A. P., Schindler, J., Krance, R. A., Heslop, H. E., Spencer, D. M., Rooney, C. M., & Brenner, M. K. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine, 365(18), 1673\u20131683. https:\/\/doi.org\/10.1056\/NEJMoa1106152","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10227_CR233","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","volume":"123","author":"X Zhou","year":"2014","unstructured":"Zhou, X., Di Stasi, A., Tey, S. K., Krance, R. A., Martinez, C., Leung, K. S., Durett, A. G., Wu, M. F., Liu, H., Leen, A. M., Savoldo, B., Lin, Y. F., Grilley, B. J., Gee, A. P., Spencer, D. M., Rooney, C. M., Heslop, H. E., Brenner, M. K., & Dotti, G. (2014). Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood, 123(25), 3895\u20133905. https:\/\/doi.org\/10.1182\/blood-2014-01-551671","journal-title":"Blood"},{"issue":"9","key":"10227_CR234","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41434-023-00404-2","volume":"30","author":"L Bouquet","year":"2023","unstructured":"Bouquet, L., B\u00f4le-Richard, E., Warda, W., Neto Da Rocha, M., Trad, R., Nicod, C., Haderbache, R., Genin, D., Ferrand, C., & Deschamps, M. (2023). RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. Gene Therapy, 30(9), 706\u2013713. https:\/\/doi.org\/10.1038\/s41434-023-00404-2","journal-title":"Gene Therapy"},{"issue":"5","key":"10227_CR235","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1182\/blood.v97.5.1249","volume":"97","author":"DC Thomis","year":"2001","unstructured":"Thomis, D. C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C., & Clackson, T. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 97(5), 1249\u20131257. https:\/\/doi.org\/10.1182\/blood.v97.5.1249","journal-title":"Blood"},{"issue":"7","key":"10227_CR236","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","volume":"28","author":"SA Richman","year":"2020","unstructured":"Richman, S. A., Wang, L. C., Moon, E. K., Khire, U. R., Albelda, S. M., & Milone, M. C. (2020). Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Molecular Therapy, 28(7), 1600\u20131613. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.004","journal-title":"Molecular Therapy"},{"issue":"4","key":"10227_CR237","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., Ma, J., Nunez, V., Shen, J., Woods, A. K., Wright, T. M., Schultz, P. G., Kim, C. H., & Young, T. S. (2016). Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A, 113(4), E459-468. https:\/\/doi.org\/10.1073\/pnas.1524155113","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7735","key":"10227_CR238","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke, V., Bai, R. Y., Kim, K., Darvas, M., Davila, M. L., Riggins, G. J., Rothman, P. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Zhou, S. (2018). Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature, 564(7735), 273\u2013277. https:\/\/doi.org\/10.1038\/s41586-018-0774-y","journal-title":"Nature"},{"issue":"6","key":"10227_CR239","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Vera, J. F. (2014). Reversal of tumor immune inhibition using a chimeric cytokine receptor. Molecular Therapy, 22(6), 1211\u20131220. https:\/\/doi.org\/10.1038\/mt.2014.47","journal-title":"Molecular Therapy"},{"key":"10227_CR240","doi-asserted-by":"publisher","first-page":"39833","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017). An oxygen sensitive self-decision making engineered CAR T-cell. Science and Reports, 7, 39833. https:\/\/doi.org\/10.1038\/srep39833","journal-title":"Science and Reports"},{"key":"10227_CR241","doi-asserted-by":"publisher","unstructured":"Gazeau, N., Liang, E. C., Wu, Q. V., Voutsinas, J. M., Barba, P., Iacoboni, G., Kwon, M., Ortega, J. L. R., L\u00f3pez-Corral, L., Hernani, R., Ortiz-Maldonado, V., Mart\u00ednez-Cibrian, N., Martinez, A. P., Maziarz, R. T., Williamson, S., Nemecek, E. R., Shadman, M., Cowan, A. J., Green, D. J., . . . Gauthier, J. (2023). Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 29(7), 430\u2013437. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.001","DOI":"10.1016\/j.jtct.2023.04.001"},{"issue":"2","key":"10227_CR242","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/S2666-6367(23)00234-8","volume":"29","author":"M Narkhede","year":"2023","unstructured":"Narkhede, M., Stasi, A. D., Bal, S., Shea, L. K., Goyal, G., Sledge, A., Hardwick, P., Giri, S., & Mehta, A. (2023). Interim analysis of investigator-initiated phase 2 trial of siltuximab in treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to CAR T-cell therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 29(2), S133\u2013S134. https:\/\/doi.org\/10.1016\/S2666-6367(23)00234-8","journal-title":"Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy"},{"issue":"10","key":"10227_CR243","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008). Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood, 112(10), 3959\u20133964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846","journal-title":"Blood"},{"issue":"20","key":"10227_CR244","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","volume":"7","author":"JM Rocco","year":"2023","unstructured":"Rocco, J. M., Inglefield, J., Yates, B., Lichtenstein, D. A., Wang, Y., Goffin, L., Filipovic, D., Schiffrin, E. J., & Shah, N. N. (2023). Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities. Blood Advances, 7(20), 6134\u20136139. https:\/\/doi.org\/10.1182\/bloodadvances.2023010708","journal-title":"Blood Advances"},{"key":"10227_CR245","doi-asserted-by":"publisher","unstructured":"Manni, S., Del Bufalo, F., Merli, P., Silvestris, D. A., Guercio, M., Caruso, S., Reddel, S., Iaffaldano, L., Pezzella, M., Di Cecca, S., Sinibaldi, M., Ottaviani, A., Quadraccia, M. C., Aurigemma, M., Sarcinelli, A., Ciccone, R., Abbaszadeh, Z., Ceccarelli, M., De Vito, R., . . . Quintarelli, C. (2023). Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nature Communications, 14(1), 3423. https:\/\/doi.org\/10.1038\/s41467-023-38723-y","DOI":"10.1038\/s41467-023-38723-y"},{"issue":"2","key":"10227_CR246","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.Bcd-21-0181","volume":"3","author":"SR Bailey","year":"2022","unstructured":"Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarf\u00f2, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., Silva, H., Lindell, K. A., Demato, A., Gallagher, K. M. E., Frigault, M. J., & Maus, M. V. (2022). Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov, 3(2), 136\u2013153. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0181","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10227_CR247","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2643-3230.Bcd-21-0203","volume":"3","author":"KO McNerney","year":"2022","unstructured":"McNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2022). Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discovery, 3(2), 90\u201394. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0203","journal-title":"Blood Cancer Discovery"},{"key":"10227_CR248","doi-asserted-by":"publisher","unstructured":"Sterner, R. M., Cox, M. J., Sakemura, R., & Kenderian, S. S. (2019). Using CRISPR\/Cas9 to knock out GM-CSF in CAR-T cells. Journal of Visualized Experiments (149). https:\/\/doi.org\/10.3791\/59629","DOI":"10.3791\/59629"},{"issue":"14","key":"10227_CR249","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019). Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Journal of Biological Chemistry, 294(14), 5430\u20135437. https:\/\/doi.org\/10.1074\/jbc.AC119.007558","journal-title":"Journal of Biological Chemistry"},{"key":"10227_CR250","doi-asserted-by":"publisher","unstructured":"Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Science Translational Medicine, 11(499). https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","DOI":"10.1126\/scitranslmed.aau5907"},{"issue":"5","key":"10227_CR251","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019). Pharmacologic control of CAR-T cell function using dasatinib. Blood Advances, 3(5), 711\u2013717. https:\/\/doi.org\/10.1182\/bloodadvances.2018028720","journal-title":"Blood Advances"},{"key":"10227_CR252","doi-asserted-by":"publisher","unstructured":"Baur, K., Heim, D., Beerlage, A., Poerings, A. S., Kopp, B., Medinger, M., Dirks, J. C., Passweg, J. R., & Holbro, A. (2022). Dasatinib for treatment of CAR T-cell therapy-related complications. Journal for immunotherapy of cancer, 10(12). https:\/\/doi.org\/10.1136\/jitc-2022-005956","DOI":"10.1136\/jitc-2022-005956"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10227-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10227-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10227-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T23:06:45Z","timestamp":1743289605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10227-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":252,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10227"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10227-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,15]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"17"}}